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The thesis constitutes the studies about the two aspects of tendon and ligament 
tissue engineering: regeneration and maturation. Injuries to tendon and ligament are 
among the most common injuries to the body, particularly in the young and physically 
active population. Associated with the problems of incomplete healing and recurrent 
injury, these injuries are not only responsible for large health care cost, but also result 
in lost work time and individual morbidity. Tissue engineering holds promise in 
treating these conditions by replacing the injured tissue with engineered tissue 
exhibited similar mechanical and functional characteristics. Collagen plays a central 
role in tendon and ligament regeneration, as collagen type I is responsible for more 
than 60% and 80% of the dry weigh of tendon and ligament structures, respectively. 
The hierarchical organization of collagen type I in bundles confers most of the 
mechanical properties of tendons and ligaments. Consequently, tendon or ligament 
tissue engineering studies are mainly focused on seeding cells into collagen gels. 
However, up to now, no cell-collagen constructs have been able to achieve sufficient 
mechanical properties and the complex architecture of the tendon and ligament is 
never fully reproduced.  
A major cause for low mechanical property of regenerating tendon or ligament 
is the slow maturation. The maturation of the engineered tissue is dominated by the 
maturation degree of extracellular matrix, such as collagen crosslink density.  To  
 ii
overcome the slow growth and maturation of tissue engineering grafts, one goal of 
this project is to accelerate the tissue maturation using gene therapeutics approach. 
Therefore, in the first part of this thesis, two different genes, lysyl oxidase 
(LOX) and decorin, were transfected into fibroblasts by retrovirus infection. LOX 
initiates the covalent cross-linking of collagen and elastin in the extracellular space by 
oxidizing specific lysine residues in these proteins to peptidyl 
α-aminoadipic-δ-semialdehyde (AAS). These aldehyde residues can spontaneously 
condense with vicinal peptidyl aldehydes or with ε-amino groups of peptidyl lysine to 
generate the covalent crosslinkages, which stabilizes and insolubilizes polymeric 
collagen or elastin fibers in the extracellular matrix. Decorin is considered a key 
regulator of matrix assembly because it limits collagen fibril formation and thus 
directs tendon and ligament remodeling due to tensile forces. In this study, we found 
that the mechanical property of the tissue-engineered grafts was significantly 
increased by over-expressing LOX or decorin gene. And decorin over-expression 
uniformed the mean diameter of the collagen fibers. 
In the second part of this thesis, ECM-based hydrogel system was used to 
control the delivery of chemotaxic growth factors, such as hepatocyte growth factor 
(HGF), for recruiting endogenous stem cells. This approach was used to attract 
endogenous stem cells to the lesion site for tendon or ligament regeneration. In this 
study, we found that stem cells could be recruited effectively to the local site where 
HGF were released by chemically modified hyaluronic acid (HA) and gelatin (Gtn) 
based hydrogels both in vitro and in vivo. 
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THESIS ROADMAP  
The thesis constitutes the studies about the two aspects of tendon and ligament 
tissue engineering: regeneration and maturation. Injuries to tendon and ligament are 
among the most common injuries to the body, particularly in the young and physically 
active population. Associated with the problems of incomplete healing and recurrent 
injury, these injuries are not only responsible for large health care cost, but also result 
in lost work time and individual morbidity. Tissue engineering holds promise in 
treating these conditions by replacing the injured tissue with engineered tissue 
exhibited similar mechanical and functional characteristics. Collagen plays a central 
role in tendon and ligament regeneration, as collagen type I is responsible for more 
than 60% and 80% of the dry weigh of tendon and ligament structures, respectively. 
The hierarchical organization of collagen type I in bundles confers most of the 
mechanical properties of tendons and ligaments. Consequently, tendon or ligament 
tissue engineering studies are mainly focused on seeding cells into collagen gels. 
However, up to now, no cell-collagen constructs have been able to achieve sufficient 
mechanical properties and the complex architecture of the tendon and ligament is 
never fully reproduced.  
A major cause for low mechanical property of regenerating tendon or ligament 
is the slow maturation. The maturation of the engineered tissue is dominated by the 
maturation degree of extracellular matrix, such as collagen crosslink density.  To  
overcome the slow growth and maturation of tissue engineering grafts, one goal of 
this project is to accelerate the tissue maturation using gene therapeutics approach. 
Therefore, in the first part of this thesis, two different genes, lysyl oxidase 
(LOX) and decorin, were transfected into fibroblasts by retrovirus infection. LOX 
initiates the covalent cross-linking of collagen and elastin in the extracellular space by 
oxidizing specific lysine residues in these proteins to peptidyl 
α-aminoadipic-δ-semialdehyde (AAS). These aldehyde residues can spontaneously 
condense with vicinal peptidyl aldehydes or with ε-amino groups of peptidyl lysine to 
generate the covalent crosslinkages, which stabilizes and insolubilizes polymeric 
collagen or elastin fibers in the extracellular matrix. Decorin is considered a key 
regulator of matrix assembly because it limits collagen fibril formation and thus 
directs tendon and ligament remodeling due to tensile forces. In this study, we found 
that the mechanical property of the tissue-engineered grafts was significantly 
increased by over-expressing LOX or decorin gene. And decorin over-expression 
uniformed the mean diameter of the collagen fibers. 
In the second part of this thesis, ECM-based hydrogel system was used to 
control the delivery of chemotaxic growth factors, such as hepatocyte growth factor 
(HGF), for recruiting endogenous stem cells. This approach was used to attract 
endogenous stem cells to the lesion site for tendon or ligament regeneration. In this 
study, we found that stem cells could be recruited effectively to the local site where 
HGF were released by chemically modified hyaluronic acid (HA) and gelatin (Gtn) 





Tendons are anatomic structures that connect muscles to bones and transmit 
the forces created in the muscles to bones making joint movements possible. Healthy 
tendons, which exhibit high mechanical strength and good flexibility, are brilliant 
white in color and fibro-elastic in texture. Tendons vary in form. They can be rounded 
cords, strap-like bands or flattened ribbons [1]. Tendons consist of collagens, 
proteoglycans, glycoproteins, water and cells. 
 
Tendon cells 
Tendon fibroblasts, including tenoblasts and tenocytes, comprise about 
90-95% of the cellular elements of the tendon. The other 5-10% includes the 
chondrocytes at the pressure and insertion sites, the synovial cells of the tendon sheath 
on the tendon surface, the vascular cells, such as capillary endothelial cells and 
smooth muscle cells of the arterioles [2, 3].  
The newborn tendon has a very high cell-to-matrix ratio. Tenoblasts are 
immature tendon cells, and they are spindle-shaped, with numerous cytoplasmic 
organelles reflecting their high metabolic activity [1]. When the cell-to-matrix ratio 
gradually decreases with aging, the tenoblasts become elongated and transform into 
tenocytes. Tenoblasts and tenocytes align in rows between collagen fiber bundles, and  
they are responsible for synthesizing extracellular matrix proteins, producing an 
organized collagen matrix and remodeling it during tendon healing [4]. 
 
Tendon extracellular matrix 
Tendons are rich in collagens, with the most abundant tendon component 
being type I collagen, which constitutes about 60% of the dry mass of the tendon and 
about 95% of the total collagen [4-6]. The remaining 5% consists of type III and V 
collagen. Type III collagen has major role in tendon early repair [7] and type V 
collagen copolymerizes with type I collagen to regulate tendon fibril diameter during 
fibrillogenesis [8] and aging [9]. 
Collagen is arranged in hierarchical levels of increasing complexity, beginning 
with tropocollagen (a triple-helix polypeptide chain), which unites into fibrils; fibers 
(primary bundles); fascicles (secondary bundles); tertiary bundles; and the tendon 
itself [10] (Figure 2.1). Soluble tropocollagen molecules form cross-links to create 
insoluble collagen molecules, which aggregate to form collagen fibrils. A bunch of 
collagen fibrils form a collagen fiber, which is the basic unit of a tendon. Collagen 
fibers are bound by endotenons, a thin layer of connective tissue that contains blood 
vessels, lymphatics and nerves [11]. Fascicles are composed of fiber bundles, and 
bundles of fascicles are enclosed by the epitenon, a fine, loose connective-tissue 
























Figure 2.1 Tendon structure from collagen fibril to the entire tendon. 
 
Besides collagens, tendons also contain proteoglycans and glycoproteins. 
There are many proteoglycans, including aggrecan and decorin [12]. Aggrecan holds 
water within the fibrocartilage and resists compression [13]. Decorin, which located in 
the tropocollagen interstices, is believed to regulate fibril diameter and to provide 
fibril-to-fibril and fibril-to-proteoglycan binding[14]. Glycoproteins present in tendon 
extracellular matrix include tenascin-C and fibronectin. Tenascin-C contributes to the 
mechanical stability of the extracellular matrix through its interaction with collagen 
fibrils [15]. Fibronectin has role in wound healing, its synthesis increases at wound 
healing [16].  
Elastin, which composes about 2% of the dry weight of the tendon, is another 
component of tendon extracellular matrix. Elastic fibers are scarcely present in human 
tendons, and it is reported that elastic fibers were actually demonstrable in only 10% 
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of healthy human tendons [17]. The function of elastic fiber is not entirely clear, but 
they may contribute primarily to the recovery of the wavy collagen fiber configuration 
after tendinous stretch [18]. 
 
Tendon mechanical properties 
Tendons transmit force generated by muscle to bone, and act as a buffer by 
absorbing external forces to limit muscle damage. Tendons exhibit high mechanical 
strength, good flexibility, and an optimal level of elasticity to perform their unique 
role [19]. Tendons are viscoelastic tissues, and they display stress relaxation and creep 
[1].  
A typical tendon stress-strain curve is shown to demonstrate the behavior of 
tendon (Figure 2.2). The mechanical behavior of tendon collagen is dependent on the 
number and types of intra- and inter- molecular bonds [20]. At rest, collagen fibers 
and fibrils display a crimped configuration. The initial concave portion of the curve is 
called toe region. This toe region, where tendon is strained up to 2%, represents the 
stretching-out the crimp pattern [18]. In the linear region of the stress-strain curve, 
where the tendon is stretched less than 4%, collagen fibers lose their crimp pattern and 
the fibers become more parallel [21]. In this region, the tendon behaves in an elastic 
fashion, and returns to its original length when unloaded. The slope of this linear 
region is referred to as the Young’s module of the tendon [4]. When the tendon is 
stretched over 4%, microscopic failure occurs. When the tendon is stretched over 

































Figure 2.2 Tendon stress-strain curve showing the initial non-linear toe region followed by a linear 
region up to a failure region. 
 
 
Tendons are viscoelastic and sensitive to different strain rates. Tendons are 
more deformable at low strain rates. Therefore, the tendons absorb more energy, but 
are less effective in transferring loads. At high strain rates, tendons become less 
deformable with a high degree of stiffness and are more effective in moving large 
loads [10]. Furthermore, tendons are at the highest risk for rupture if tension is applied 





Ligament is fibrous tissue that connects bones to other bones. Ligament is 
composed of closely packed collagen fiber bundles organized mostly in a parallel 
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configuration along the length of the tissue to resist tensile loads [22]. So, ligament 
and tendon have a similar hierarchical structure that affects their mechanical behavior.  
 
Ligament cells 
Fibroblast is the major cell type of ligament. The cells are relatively few in 
number and represent a small percentage of the total ligament volume. Fibroblasts are 
not only responsible for collagen synthesis but also for collagen renewal process, 
which includes enzymatically breaking down and removing old collagen [23].  
 
Ligament extracellular matrix 
Ligaments are approximately two-third water and one-third solid. Water is 
responsible for contributing to cellular function and viscoelastic behavior. The solid 
components of ligaments are principally collagen. The most abundant ligament 
component is type I collagen, which constitutes about 80% of the dry mass of the 
ligament and about 85% of the total collagen [24]. The rest collagens in ligament 
include collagen type III, V, VI, XI, and XIV. Type III and V collagen make up 8% of 
and 12% of the dry weight of the ligament, respectively, and they have been shown to 
be involved in regulating collagen fibril diameter [25]. Besides collagen, ligaments 
also contain proteoglycans, elastin, glycoproteins such as actin, laminin and integrins 
[24]. 
Collagen is arranged in hierarchical levels in ligament, which is similar as in 
tendon. Briefly, collagen molecules assemble sequentially into microfibrils, subfibrils, 
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and fibrils (20-150nm in diameter) before forming fibers, which are 1-20μm in 
diameter [23]. Crosslinked fibers further make up a subfascicular unit, which is 
surrounded by a loose band of connective tissue called endotenon. The diameter of 
subfascicular units is 100-250μm. Three to twenty subfasciculi subsequently form a 
fasciculus (from 250μm to several millimeters in diameter)[23]. The fasciculus are 




Tendon and ligament injuries 
Tendon injuries are among the most common injuries to the body, particularly 
in the young and physically active population. The most common tendon disorders are 
observed in the Achilles tendon (100,000 per year) [26], in the rotator cuff in the 
shoulder (51,000 per year) [27], and patellar tendon donor autograft injuries in the 
knee (42,000 per year) [22].  
Tendon injuries can be acute or chronic, and are caused by intrinsic or 
extrinsic factors, either alone or in combination. Acute injuries typically arise from 
trauma, whereas chronic injuries often occur after repetitive subfailure mechanical 
events followed by inflammation [28, 29]. Chronic injuries can be associated with 
inflammation (tendonitis), without inflammation (tendinosis), or involve the 
surrounding tissue (peritendinitis) [19].  
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Acute tears of rotator cuff tendons commonly occur in athletes participating in 
overhead sports [30], whereas chronic degeneration and tearing tend to occur in older 
more sedentary subjects [27]. The Achilles tendon is often injured traumatically, but it 
is also frequently involved in chronic injuries. Acute Achilles tendon injury and pain 
usually occur in active individuals, when the tendon is subjected to high or unusual 
loads. In contrast to acute injuries, Achilles tendinopathies are caused by repeated 
microinjuries coupled with a degenerative or failed healing response [31]. 
Ligaments are most often torn in traumatic joint injuries that can result in 
either partial or complete ligament discontinuities. For example, over 100,000 anterior 
cruciate ligament (ACL) ruptures estimated to occur each year in the United 
States[32]. All of these tendon and ligament disorders can bring significant morbidity 
and decrease the quality of life. 
 
 
Tendon and ligament healing 
When tendons or ligaments are injured, the body initiates a process of healing. 
Tendon and ligament healing can be largely divided into three overlapping phases: the 
inflammatory, repairing, and remodeling phases [33].  
The initial inflammatory phase lasts about 24 hours. In this phase, erythrocytes, 
platelets and inflammatory cells (neutrophils, monocytes, macrophages) migrate to the 
wound site and clean the site of necrotic materials by phagocytosis. In the mean time, 
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these cells release vasoactive and chemotactic factors, which recruit fibroblasts to 
begin collagen synthesis and deposition [4]. During this phase, there is an increase in 
fibronectin, glycosaminoglycan, water, and collagen type III content, which 
collectively stabilize the newly formed extracellular matrix [10]. A few days after the 
injury, the repairing phase begins. This phase lasts a few weeks. In this phase, the 
predominant cell types are fibroblasts along with a smaller number of macrophages 
and mast cells [34]. Fibroblasts synthesize abundant collagen and other extracellular 
matrix components such as proteoglycans and deposit them to the wound site. 
Synthesis of type III collagen peaks during this stage, water content and 
glycosaminoglycan concentrations remain high [1]. About 6 weeks later, the 
remodeling phase begins. In this phase, fibroblasts decrease in size and slow their 
matrix synthesis, and collagen fibers begin to orient themselves longitudinally along 
the long axis of the tendon or ligament. The repair tissue changes from cellular to 
fibrous, which again changes to scar-like tendon tissue after 10 weeks [1]. When the 
scar enters maturation, type III to type I collagen ratio, collagen crosslinks, and 
glycosaminoglycan, and water concentrations approach normal levels. During the 
later remodeling phase, covalent bonding between collagen fibers increases, which 
results in repaired tissue with higher stiffness and tensile strength [4]. Although the 
tensile strength of the healing tissue improves over time, it does not reach the levels of 
uninjured, normal tissue (Figure 2.3) [34]. Despite remodeling, the biochemical and 
mechanical properties of healed tissue never match those of intact tendon. In normal 
tendon or ligament, the collagen fibers are all arranged in a vertical alignment to best 
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withstand the force that the tendon or ligament would be loaded; while in repaired 
scar tissue, the collagen fibers are randomly arranged in many directions. Also the 
healed tissue is unable to recover normal crosslink density, it may be because of the 
alteration in the proportion of collagen types, proteoglycans and other unknown 
factors within the wound environment [33]. Mechanically, healed tendons or ligament 
do not achieve normal tissue failure force in the long term. Butler et al reviewed that 
1.5 months after creating a defect injury in the patellar tendon, the repair tissue 
achieves 7-9% of normal failure force and by 3 and 6 months after injury, repair tissue 










































Traditional Treatments for tendon and ligament injuries 
Because tendons and ligaments heal poorly, there are many different types of 
treatment used in tendon and ligament disorders, such as physical therapy, reduction 
of inflammation, restoration of flexibility and surgical repair [27, 35-37]. Some 
current treatments and some therapies in development will be introduced in the 
following paragraphs. 
 
Clinical used treatments 
Sutures There are a variety of different suture techniques used clinically, each with 
their preferred suture material that may be employed at the discretion of the surgeon. 
Some of these techniques include Lin locking [38], Savage [39], Kessler [40], 
modified Kessler [39], and epitenon suture [41] method. It has been shown that the 
repair strength is directly proportional to the number of strands crossing a repair site, 
ruptures usually occur at the knots in the suture, and epitenon sutures increase repair 
strength over core sutures alone [34, 41]. 
Eccentric exercise therapy Eccentric strength training is particularly effective in 
treating tendinopathies and helps promote the formation of new collagen [42]. 
Eccentric contraction involves the lengthening of muscle fibers as the muscle 
contracts, preferentially loading the tendon [43]. Eccentric exercise has proved 




NSAIDs Nonsteroidal anti-inflammatory drugs (NSAIDs) effectively relieve 
tendinopathy pain and may offer additional benefit in acute inflammatory tendonitis 
because of their anti-inflammatory properties. However, because the majority of 
chronic tendinopathies are not inflammatory, few data exist to support the use of 
NSAIDs over analgesics without anti-inflammatory effects [43]. 
Other therapies include cryotherapy (reduction of acute inflammation and decrease in 
cell metabolism [44]), heat treatment (stimulation of cell activity and increase of 
blood flow [44]), and physiotherapy (same as heat treatment).  
 
Treatments under development 
Laser treatment Low-level laser therapy (LLLT) is using of low-power lasers and 
superluminous diodes for the treatment of a variety of medical conditions, and it now 
has been known as a possible treatment for tendon and ligament injuries. LLLT can 
enhance ATP production, enhance cell function and increase protein synthesis [45]. 
LLLT has also been shown to have positive effects on reduction of inflammation, 
increase of collagen synthesis, and angiogenesis [45]. There have been a few studies 
regarding effects of LLLT on tendon and ligament repair [45, 46].  
Corticosteroid injection Corticosteroids may reduce inflammation and inhibit protein 
synthesis [44]. Injected corticosteroids may be more effective than oral NSAIDs for 
relief in the acute phase of tendon pain, but they do not tend to alter long-term 
outcomes. The effects of peritendinous corticosteroid injections are unknown, but they 
should be used with some caution [43]. Because the role of inflammation in 
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tendinopathies is unclear, corticosteroids may serve only to inhibit healing and reduce 
the tensile strength of the tissue, predisposing to spontaneous rupture [43]. 
Other treatments under development include shock-wave therapy (stimulate 
tenocyt







Many people suffer from tendon and ligament diseases each year. For example, 
100,00
es for repair), nitroglycerin patches (enhance collagen synthesis), and 
sclerosant injections (block tendon blood flow) [44]. 
There are many drawbacks of existing treatm
 characteristic response to injury is for fibroplasias to occur, which inevitable 
leads to scar tissue in the tendon or ligament. Although remodeling of the scar tissue 
occurs over time, the subsequent tissue is not normal and, in particular, has less 
compliance and functionality than the original tendon and ligament matrix [47]. 
As a result of the deficiencies of current treatment, there is great inter
ating the potential for tissue engineering in tendon and ligament injuries. 
0 people suffer from Achilles tendon disorders every year, 51,000 people suffer 
from rotator cuff tendon disorder each year, and over 100,000 anterior cruciate 
ligament (ACL) ruptures estimated to occur each year in the United States [32]. 
Associated with the problems of incomplete healing and recurrent injury, these 
injuries are not only responsible for large health care costs, but also result in lost work 
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time and individual morbidity [48]. The rate at which these injuries have increased 
and the degree to which costs have as well. For example, between 1992 and 1999, 
total knee replacement increased over 77.8%, at a compounded annual rate of 15.5% 
[49]. Surgical repair, artificial prostheses, mechanical devices, and both autographs 
and allografts continue to be important in medical treatment of certain tendon 
disorders. However, there are drawbacks of these traditional treatments for tendon 
repair. For example, prosthetic devices have complications such as durability and poor 
long-term performance, and allografts have drawbacks such as donor scarcity, 
donor-site morbidity, tissue rejection, and disease transmission. Tissue engineering 
holds promise in treating these conditions by replacing the injured tissue with 
engineered tissue with similar mechanical and functional characteristics [50]. 




i, is “an interdisciplinary field that applies the principles of engineering and life 
sciences toward the development of biological substitutes that restore, maintain, or 
improve tissue function or a whole organ” [50]. In other words, tissue engineering is 
the use of a combination of cells, engineering and materials methods, and suitable 
biochemical and physio-chemical factors to improve or replace biological functions. 
The basic concept of tissue engineering includes a scaffold that provides a
cture on which seeded cells can organize and develop into the desired organ or 
tissue prior to implantation. The scaffold provides an initial biomechanical profile for 
the replacement tissue until the cells produce an adequate extracellular matrix. During 
the formation, deposition, and organization of the newly generated matrix, the 
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scaffold is either degraded or metabolized, eventually leaving a vital organ or tissue 






Figure 2.4 Concept of tissue engineering. 
a, Cells are harvested from autologous; b, cells are harvested from allogenic or xenogenic sources; c, 
cell proliferation in vitro; d,cells reinjected to the patient 
 
Tissue Engineering Treatment For Tendon and Ligament Repair 





















 are seeded to a scaffold; e, expanded cells 
without scaffold material; f, expanded cells reinjected to the patient with scaffold; g, cells are cultured 
in bioreactor; h, cultured cells reinjected to the patient. 
 
ue engineering. In this part, these four components are reviewed for tendon and 
ligament tissue engineering. 
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Biomaterial and Scaffold 
There are several requirements govern the choice of materials for tendon and 
ligament tissue engineering. Firstly, the material must be biocompatible and 
non-toxicity [52]. The material must not cause abnormal responses in local tissues 
surrounding the implant and should not produce toxic or carcinogenic effects. 
Secondly, the material should avoid infection, so that the material should be 
sterile-able before seeding the cells onto the scaffold, and should remain sterile prior 
to surgical implantation. The sterilization technique should be carefully chosen to not 
to alter the mechanical and physical properties of the material. Finally, the scaffold 
material should provide some mechanical integrity initially to replace the function of 
the lost tendon or ligament before the scaffold degrades and is replaced with new 
extracellular matrix. Importantly, tendon and ligament have highly hierarchal 
organized collagen structure, so the further requirement of the scaffolds for tendon 
and ligament repair is that the scaffolds need the similar micro and macro morphology 
as tendon and ligament.  
As mentioned above, collagen type I constitutes about 60% of the dry mass 
of the tendon and 80% of the dry weight of ligament, its hierarchical organization in 
bundles confers most of the tendon and ligament mechanical properties, collagen 
plays a central role in tendon and ligament tissue engineering. Collagen gels have 
been used as model system for in vitro tissue engineering [53, 54], and could be used 
to assess the effects of different stimuli on cell proliferation. Also, the collagen gels 
have been used as a vehicle to deliver mesenchymal stem cells in defects of the 
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rabbits in vivo [55]. It is also reported that preliminary alignment of the cells in the 
gel increases the efficiency of the method [56]. But the collagen constructs are not 
able to achieve sufficient mechanical properties, and the complex architecture of the 
tendon is never fully reproduced. 
Although collagen type I play a central role in tendon and ligament tissue 
engineering, collagen type I does not account for all the tissue properties. The 
proteoglycans and small leucine rich protein (SLRP) also play important roles in the 
organization and mechanical properties of the tendon and ligament structure [57]. 
Collagen cross-linking has been proposed to enhance early mechanical properties, and 
this will be discussed in detail later. Besides collagen, chitin-based [58] and 
chitosan-based [59, 60] scaffolds also have been reported used for tendon tissue 
engineering. 
Except the materials from nature, some synthetic materials have been reported 
used for tendon repair. Knitted poly (D,L-lactide-co-glycolide) (PLGA) scaffolds have 
been shown to possess good mechanical strength and internal communicating spaces 
and have been effectively used for rabbit Achilles tendon repair [61]. Recently, 
electrospin technique has been employed to modify the polymers to facilitate cell 
attachment, new ECM deposition, and tissue formation for better tendon repair [62].  
Cell 
Fibroblast: There are two types of tendon fibroblast cells in tendon, tenocytes and 
tenoblasts. And fibroblast is major cell type in ligament. Some studies have been done 
using fibroblasts for tendon and ligament repair in animal models [63, 64].  
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Stem cells: Stem cells are very attractive cell sources for tendon tissue engineering. 
Stem cells are undifferentiated cells and have the ability to self-renew and 
differentiate to one or more types of specialized cells. Stem cells can be classed to two 
types: embryonic stem (ES) cells and adult stem cells. ES cells are from blastocysts 
and fetal tissue. And they have potential in the field of tissue engineering and 
regenerative medicine because they have the potential to produce most types of cells 
in the body [65-67]. Although the potential of ES cells in tissue engineering is vast, 
there are many problems must be overcome. For example, human ES cells may be 
contaminated by animal cells or proteins. It is reported that nonhuman protein 
expressed by human ES cell lines grown on animal feeder layers [68]. Other problems 
such as immunorejection and tumorigenesis are also obstacles for the clinical 
applications of ES cells. Currently, no embryonic stem cells-base therapies are 
approved for human use. 
Adult stem cells are undifferentiated cells, which are found among 
differentiated cells in a tissue or organ. Adult stem cells can renew themselves and they 
can give rise to mature cell types that have characteristic morphologies and specialized 
functions. Adult stem cells are rare, but they are located in various tissue niches 
throughout the body, including bone marrow, brain, liver, skin, blood, etc. [69].  
Mesenchymal stem cells (MSCs) have attracted much attention because of 
their multipotential properties with regard to differentiation, and their possible use for 
cell and gene therapy. MSCs reside in diverse host tissues, bone marrow was considered 
to be the most accessible and enriched source of MSCs [70]. Also, MSCs have being 
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isolated from various tissues, such as cartilage [71], periostium [72], synovium [73], 
synovial fluid [74], muscle [75] and tendons [76]. Fetal tissue [77], placenta, umbilical 
blood and vasculature [78] also have been reported to contain MSCs. MSCs retain the 
ability to differentiate into a variety of cell types, including adipocytes [79], 
chondrocytes [80], osteoblasts [79], skeletal muscle cells [81], and so on. Several 
methods are currently available for isolation of MSC based on their physical and 
physicochemical characteristics, for example, adherence to plastic or to other 
extracellular matrix components. Their wide extend resources, multipotency of 
differentiation, ease of isolation and their highly reduced immunoreactivity after 
allogenic transfer make MSCs an ideal cell type for tissue repair and regeneration in cell 
therapy applications. Several studies have demonstrated the possible use of MSCs in 
transplantation for systemic diseases, or implantation to repair local tissue defects. 
Several in vivo and in vitro experiments have demonstrated the potential of MSCs 
isolated from bone marrow [82] or from adipose tissue[83] for tendon engineering. 
Under mechanical stimulation, MSCs differentiated in fibroblasts, aligned themselves in 
collagen gel, and helped in vivo tendon regeneration.  
Although using MSCs for tissue repair is very promising, there are still issues 
related to the application of MSCs for human use. For example, the pluripotency of 
MSCs would decrease during in vitro propagation [84, 85]. The cost of in vitro process 
for cell propagation and transplantation is high. To overcome this problem, we are 
developing a new strategy to use endogenous stem cells for tissue repair. The detail will 
be discussed later. 
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Growth Factor 
The main growth factors that affect growth and differentiation of ligament and 
tendon tissue include basic fibroblast growth factor (bFGF), platelet-derived growth 
factor (PDGF), epidermal growth factor (EGF), insulin-like growth factor (IGF)-1, 
and members of the family of TGF-β/bone morphogenetic proteins (TGF-β/BMPs). 
bFGF is the major mitogenic agent for fibroblasts, and it increases cell 
proliferation of rat tenocytes [86]. Injection of bFGF results in a dose-dependent 
increase of cell proliferation and collagen type III production [87]. PDGF is also an 
important mitogenic agent for fibroblasts [86]. Researches found that enhanced 
expression of PDGF-BB in healing ligament led to an initial promotion of 
angiogenesis and subsequent enhanced and accelerated matrix deposition[88]. And it 
is also reported that PDGF-BB could augment tendon repair in a rotator cuff injury 
model [89]. IGF-1 provides some anti-inflammatory functions and also acts as a 
chemotactic attractant for endothelial cells[90]. It was reported that via a possible 
anti-inflammatory mechanism, IGF-1 could reduce maximum functional deficit and 
accelerate recovery after Achilles tendon injury[90]. 
The growth factors can be delivered locally, but they are easy to be over 
loaded. It is important to understand the right time for the administration of growth 
factors and their dosage for effective therapies.  
Bioreactor 
Bioreactors, which provide dynamic loading, are essential for meeting the 
complex requirements of in vitro engineering of functional skeletal tissues. It is 
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reported that an increase in cell proliferation, migration and collagen synthesis has 
been observed in lacerated chicken tendon cultured in vitro undergoing cyclic tension 
after 14 days [91]. Some studies demonstrated that cyclic strain (5%, 1Hz, for 15 or 
minutes) could increase TGF-β, bFGF, and PDGF production in human tendon 
fibroblasts [92], cyclic mechanical stretching (8%, 0.5HZ, for 4 hours) slightly but 
significantly increases tendon proliferation on a microgrooved substrate, and increases 
collagen type I and TGF-β expression [93]. And there are some bioreactors designed 
specifically for ligament tissue engineering. For example, Altman and his colleagues 
designed an advanced bioreactor, which provided the application of multidimensional 
mechanical strains (axial tension/compression and torsion) to MSC cultured in a 
hydrogel or on a fibrous scaffold [94]. The mechanical stimulation induced cell 
alignment in the direction of the resulting force, and fostered the expression of 
collagen type I and type III and tenascin C [94]. 
In conclusion, well combination of the four components (cell, scaffold, growth 
factor and bioreactor) is very important for the success of tendon and ligament tissue 
engineering. 
 
Two major strategies may be applied for tendon tissue engineering. One is the 
in vivo approach of tendon engineering involving in situ delivery of cells, 
biomolecules, hydrogels or scaffolds to boost the regeneration and healing process to 
deal with the repair of small defects and the induction of tissue self-regeneration [88]. 
The other is the in vitro tissue engineering involving the growth of tendon-like tissue 
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structure outside of the body and the implantation into the defect. This strategy is 
more concerned with larger defects or tissue replacement. 
 
 
Tendon and Ligament Maturation 
The overall shape and function, in terms of flexibility and locomotion, of the 
human skeletal system depend on a basic framework of collagen fibers [95]. The 
collagen fibers are essentially in extensible and therefore provide mechanical strength 
and through that strength confer and maintain form whilst allowing flexibility 
between various organs of the body. The collagen fibers of tendons are aligned in 
parallel and therefore loaded instantly, permitting maximum transfer of the energy of 
muscle contraction to the bone. 
 
Collagen 
The collagen molecule, also called tropocollagen, is composed of three 
intertwined polypeptide chains. Each of the polypeptides that constitute the collagen 
molecule is designated as an α-chain. They intertwine, forming a right-handed triple 
helix. Except at the ends of the α-chain, every third amino acid in the chain is a 
glycine molecule because glycine is the smallest amino acid. A hydroxyproline 
frequently precedes each glycine in the chain, and a proline frequently follows each 
glycine in the chain. The glycine, along with proline and hydroxyproline, is essential 
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for the triple-helix conformation. Sugar groups, which are joined to hydroxylysyl 
residues, are associated with the helix. Because of these sugar groups, collagen is 
properly described as a glycoprotein [96]. The α-chains that constitute the helix are 
not all alike, and according to differences in α-chains and differences in molecules 
organization and arrangement, as many as 28 different types of collagen have been 
described in literature. Tendon and ligament are predominantly fibrous Type I 
collagen. 
The production of fibrillar collagen involves a series of events within the cells 
that leads to the production of procollagen, the precursor of the collagen molecule. 
The production of the actual fibril occurs outside of the cell and involves enzymatic 
activity at the plasma membrane to produce the collagen molecule, followed by the 
assembly of the molecules into fibrils under guidance of the cell. Most of the 
synthesis of procollagen is in the rough endoplasmic reticulum (RE). Soluble 
procollagens are “packaged” in the Golgi apparatus to be excreted to outside the cell. 
Then the procollagen stays close to the cell surface where most of maturation occurs. 
The procollagen moves to the exterior of the cell by means of exocytosis of secretory 
vesicles. Then the procollagen, on secretion from the cell, is converted to collagen 
molecules by procollagen peptidase, which cleaves the uncoiled ends of the molecule. 















Figure 2.5 Schematic diagram showing the different posttranslational modifications and assembly of 
type I collagen into fibrils [96]. Procollagen consists of a 300-nm-long triple-helical domain flanked by 
a trimeric globular C-propeptide domain and a trimeric N-propeptide domain. Procollagen is secreted 
from cells and is converted into collagen by the removal of the N- and C-propeptides by procollagen 
N-proteinase and procollagen C-proteinase respectively. The collagen generated in the reaction 
spontaneously self-assembles into cross-striated fibrils that occur in the extracellular matrix of 
connective tissues. The fibrils are stabilized by covalent cross-linking, which is initiated by oxidative 




Collagen maturation occurs outside the cell. Once outside the cell, an 
enzyme-mediated cross-linking takes place and the triple helical collagen molecules 
line up and begin to form fibrils and then fibers. The cross-linking mechanism in the 
fibrillar collagens is based upon aldehyde formation from the single telopeptide lysine 
or hydroxylysine residue. This step is initiated by a specialized enzyme called lysyl 
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oxidase (LOX), which oxidatively deaminates these residues to promote crosslink 
formation. Once LOX deaminates the residues to initiate the cross-linking, the 
subsequent reactions of the aldehydes are spontaneous and governed by 
post-translational modifications and the structural organization of the collagen. Two 
major cross-links are aldimines which are formed by telopeptide lysine-aldehydes 
condense with either lysine or hydroxylysine residues in the conserved sequence of 
the triple helix and keto-imines which are formed by hydroxylated telopeptide 
lysine-aldehyde reacts with the ε-amino group of a helical hydroxylysine [97]. Other 
forms of cross-links such as aldol-derived cross-link that is formed by reaction of the 
intramolecular aldol condensation product with histidine also exist. The formation of 
cross-links in mature collagen creates stability and gives definition to the structure. 
The majority of tendons and ligaments contain both the aldimine and the keto-imine 
corss-links. The ratio depends upon the particular function of the tissue, in particular 
whether there is tension on the tissue. 
Besides aldehyde formation, another kind of intermolecular cross-linking of 
collagen which will increase with age is glycation. Glycation can affect the properties 
of collagen in a number of ways, for example, its ability to form precise 
supramolecular aggregates, the alteration of its charge profile and hence its interaction 
with cells, and, additionally, glycated collagen can act as an oxidizing agent [97]. 
Increasing collagen cross-linking of engineered tissue may enhance 
mechanical stability. Some strategies have been investigated to increase collagen 
cross-linking. Besides enzymatic cross-linking (initiated by LOX) and glycation, 
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which mimic the physiological cross-linking, chemical processing, is another method 
for cross-linking. But the chemically cross-linked engineered tissue may subject to 
calcification in vivo. And glycation increases a tissue’s platelet aggregation potency 
and increases the potential for thrombosis formation. And glycation is widely known 
because of the side effect of diabetes when too much glycation occurs [98, 99]. 
Collagen cross-links formed by the lysyl oxidase (LOX) have no known negative side 




The LOX family consists of five members: LOX and four known family 
members called Lysyl oxidase-like (LOXL [100], LOXL2 [101], LOXL3 [102], and 
LOXL4 [103]). The LOXLs are isoenzymes: enzymes that have the same catalytic 
activity as LOX but different construction. They have related by different functions 
including cell growth control, tumor suppression, senescence and chemotaxis [104]. 
LOXL2, LOXL3, LOXL4 create a subfamily characterized by the presence of four 
scavenger receptor cysteine-rich (SRCR) domains [103]. 
Protein-lysine 6-oxidase (lysyl oxidase, LOX; EC 1.4.3.13), which is 
expressed and secreted by fibrogenic cells, is a copper amine oxidase. LOX initiates 
the covalent cross-linking of collagen and elastin in the extracellular space by 
oxidizing specific lysine residues in these proteins to peptidyl 
α-aminoadipic-δ-semialdehyde (AAS). These aldehyde residues can spontaneously 
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condense with vicinal peptidyl aldehydes or with ε-amino groups of peptidyl lysine to 
generate the covalent crosslinkages, which stabilize and insolubilize polymeric 
collagen or elastin fibers in the extracellular matrix [105]. LOX plays a central role in 
the morphogenesis and repair of connective tissues of the cardiovascular, respiratory, 
skeletal, and other systems of the body. 
Lysyl oxidase is synthesized in a precursor form as the 50kDa, N-glycosylated 
prolysyl oxidase (pro-LOX). Pro-LOX is secreted to the extracellular space where it 
undergoes activation to the 32 kDa, functional catalyst by proteolytic cleavage at a 
specific Gly-Asp bond [106].  
Lysyl oxidase contains two cosfactors, Cu (II) and a peptide-linked carbonyl 
residue, at its active site essential to its catalytic function. The carbonyl cofactor 
contains an ortho-quinone function and has been identified as lysine tyrosylquinone 
(LTQ), derived by oxidative post-translational modification of a specific tyrosine 
residue (tyrosine 349 in rat pro-LOX) to a dihydroxyphenylalanine (DOPA) quinone 
residue. Subsequently, the amino group of a specific lysine residue (lysine 314 in rat 
pro-LOX) covalently bonds to a ring carbon of peptidely DOPA quinone [107] (Figure 
2.6). Copper in lysyl oxidase appears to be involved in the transfer of electrons to and 
from oxygen to facilitate the oxidative deamination of targeted peptidyl lysyl groups 
in tropocollagen or tropoelastin and to internally catalyze quinone cofactor formation 
[108]. LOX catalyzes primary amine oxidation through a ping pong bi ter kinetic 


























LOX for many years was unable to be studied because LOX aggregates in 
most solutions. When it was found that when urea is added to the solution LOX 
became soluble and that urea can be easily separated, LOX studies began intearnest. It 
was found that LOX is essential in the functioning of embryonic cardiovascular 
system [110], and lungs [110]. It also is important in wound healing and has possible 
chemotaxic effects especially to monocytes. LOX has also been shown to enhance 
mechanical properties in vascular tissue scaffolds [112].  
 
Decorin 
Proteoglycans (PGs) play a crucial role in collagen fibrillogenesis, and 
therefore in tendon function. PGs are composed of a core protein to which one or 
more GAG chains are covalently attached. 
Decorin is the most abundant tendon PG. Decorin is a member of the small 
leucine-rich proteoglycan (SLRP) family, a group of secreted proteins that includes 
biglycan, fibromodulin, lumican, and keratocan, among others [113-115]. SLRPs play 
major roles in collagen fibrillogenesis, growth factor modulation, and direct 
regulation of cellular growth [116-118].  
Fibroblast, chondrocytes, endothelial cells and smooth muscle cells are 
decorin-producing cells. Decorin is composed of three domains: an N-terminal region 
which possesses a single chondoitin/dermatan sulfate side chain and a distinct pattern 
of Cys residues (CX3CXCX6C), a central region composed of ten leucine-rich repeats 
which are believed to be the prime sites of interaction with other proteins, and another 
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Cys-rich C-terminal region [119]. Positioning of collagen in the model is consistent 
with other evidence that the central leucine-rich repeats comprise the high-affinity 
collagen-binding site [120, 121]. It is believed that decorin likely maps to a narrow 
region near the C-terminus of collagen type I, very close to none of its major 
intermolecular cross-linking sites [119]. Decorin is considered a key regulator of 
matrix assembly because it limits collagen fibril formation and thus directs tendon 
remodeling due to tensile forces [122, 123]. The assumed location of decorin on 
collagen fibrils in vivo and its ability to retard collagen fibrillogenesis in vitro suggest 
that it has a role in the collagen network organization and in the maintenance of tissue 
integrity [124]. Thus absence of decorin might affect not only fibril formation but also 




Although the direct application of human recombinant proteins can result in 
beneficial effects on the healing process, high dosages and repeated injections of these 
proteins are often required due to their relatively short biological half-lives [125]. In 
addition, the use of growth factor proteins to promote healing is severely hindered by 
the difficulty of ensuring their delivery to a specific injured site [125]. Combined 
tissue engineering, gene therapy is a very promising strategy to overcome the 
problems of protein therapy. For example, cell isolated from the patients could be 
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genetically engineered to express a given therapeutic gene, and then seeded into a 
particular scaffold. After in vitro proliferation, the cells can be transplanted back to 
the patient to promote tissue regeneration. 
Gene therapy is the science of the transfer of genetic material into individuals 
for therapeutic purposes by altering cellular function or structure at the molecular 
level. By employing these techniques, genes can be used therapeutically to produce 
proteins to treat and potentially cure diseases [126]. 
 
Vectors 
In order for target cells to produce the protein products of the introduced gene, 
the exogenous genetic material must be delivered to the cell’s nucleus. This process of 
transfection exists in two classes of vectors: viral and non-viral.  
The non-viral vectors are usually easier to produce and result in lower toxicity 
and immunogenicity. The use of non-viral vectors can be in the form of injections of 
naked DNA (usually plasmids), liposomes, or particle-mediated gene transfer. The 
genetic material can be placed in liposomes in order to increase DNA uptake in tissue 
culture. But non-viral gene delivery efficiency is hindered by a low transfection rate, 
the success associated with non-viral vector usage remains limited. 
Currently, viral vectors represent a more efficient method of gene delivery 
[127, 128]. The most commonly used viruses are adenovirus, retrovirus, 
adeno-associated virus, and herpes simplex virus.  
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Retroviruses are RNA viruses that carry a gene for a reverse transcriptase that 
transcribes the viral genetic material into a double-stranded DNA intermediate. This 
DNA intermediate is then incorporated into the host DNA allowing the host cell 
machinery to produce all the necessary viral components. Because the viral genome is 
stably integrated into the host DNA, any modification that has been made will be 
passed to all daughter cells that are derived from the transfected cells [129].  
In contrast to retroviruses, adenovirus does not integrate its genome into the 
host genome. Instead, the adenoviral genome remains in the nucleus as an episomal 
element after infection of the host cell. Adenoviral vectors are ease of purification and 
concentration, and they could infect various cell types, dividing or non-dividing, at 
high efficiency rate [129].  
Adeno-associated virus requires a helper virus such as adenovirus or herpes 
simplex virus for replication. Adeno-associated virus is actually a member of the 
parvovirus family of single-stranded DNA viruses. The small size of the genome 
allows for easy manipulation such that shuttle vectors carrying the entire genome have 
been constructed. This virus is non-pathogenic and not associated with any known 
disease but can infect a wide variety of cells, dividing or non-dividing, although with 
varying levels of efficiency [129].  
Herpes simplex virus vectors can infect most cells including non-dividing cells, 
and they have large carrying capacity and ability to insert expression cassettes into 
specific loci of the genome that allows for the construction of vectors able to express 
multiple transgenes [130]. 
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Strategies 
There are two general ways that gene therapy can be performed: a direct in 
vivo method and an indirect ex vivo method. The direct method involves transferring 
the genetic material into the target somatic cells in vivo. The indirect technique 
involves removal of cells from the patient followed by genetic modification of the 
cells ex vivo and return of the cells to the patient. The direct method is technically 
simpler, while the indirect gene delivery technique is safer because the gene 
manipulation takes place under controlled conditions outside the body [32]. 
Furthermore, this method allows for selection of the cells that express the therapeutic 
gene at higher levels [131]. The choice of the strategy depends on the disease to be 
treated, the gene to be delivered to treat the disease and the vector used to deliver the 
gene.  
In the study presented in this thesis, LOX or decorin transfected retrovirus 
were used to infect mouse embryonic fibroblasts (MEF) to accelerate collagen 
maturation for tendon or ligament regeneration through an indirect ex vivo strategy. 
 
 
Stem Cells Recruitment 
A classic concept of tissue repair holds that inflammatory cells enter the 
damaged tissue or damaged tissue secret signaling molecules and signal resident cells 
mitosis. Several studies suggest that multipotent stem cells can also contribute to 
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tissue repair after mobilization, migration and engraftment into the damaged tissue 
[132]. In addition, circulating immature cells seem to participate in regeneration of 
many different tissues [133, 134]. Some models show the role of stem cells in tissue 
remodeling, such as for hepatic regeneration [135, 136], muscle regeneration [137, 
138] and infracted myocardium [139, 140]. It is not surprising that using endogenous 
stem cells have attracted lots of attention because they hold great therapeutic potential 
for endogenous tissue repair and tissue engineering.  
 
Stem cell mobilization 
Stem cell mobilization is to release of stem cells from their local niche into the 
circulation in response to chemotherapy or cytokine stimulation, which was first 
documented in the late 1970s and 1980s [141]. Mobilizing cells is a preferable 
strategy for clinical use since this may allow higher yield of these cells, faster 
engraftment and lower procedural risks compared with traditional stem cell 
transplantation approach. Several molecules, such as granulocyte colony-stimulating 
factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem 
cell factor (SCF), and IL-8, IL-12, and stromal cell derived factor-1 (SDF-1)[142] are 
shown to be able to mobilize endogenous stem cells into circulation. These molecules 
differ in their time frame to achieve mobilization, the type of cells mobilized and 
efficiency. G-CSF is the most commonly used agent, usually administrated daily at a 
dose of 5-10μg/kg for 5-10 days [141]. It has been shown that G-CSF could mobilize 
more CD34+ cells and have less toxicity than any other single agent. GM-CSF as a 
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single agent is used less often today for mobilization than G-CSF, because it 
mobilizes somewhat less well than G-CSF and because of relatively higher incidence 
of both mild and severe side effects [143]. SDF-1 is an α-chemokine that strongly 
chemoattracts hematopoietic stem/progenitor cells (HSPCs) through interaction with 
their unique receptor CXCR4. It has become evident that the SDF-1-CXCR4 
signaling axis plays an important role in the homing and engraftment of HSPCs in the 
bone marrow [144].  
Stem cells also migrate to nonhematopoietic organs, such as the liver, 
especially during liver injury/inflammation which creates an alarm situation and 
transmitting stress signals that mobilize and recruit stem cells as part of organ repair. 
 
Hepatocyte growth factor (HGF) 
Hepatocyte growth factor (HGF) is a pleiotropic cytokine of mesenchymal 
origin, promoting motility, proliferation, invasion, morphogenesis and survival of a 
wide spectrum of cells, namely epithelial and endothelial cells [145]. The coordinated 
integration of these processes plays a pivotal role in organ formation during 
embryogenesis and tissue homeostasis in adults. In adults, HGF displays in vivo 
cytoprotective activity in different cell types of injured organs. It is reported that HGF 
is able to enhance mesenchymal stem cells engraftment in injured heart [146]. Many 
researches have demonstrated that HGF could activate mesenchymal stem cells 
migration in vitro [144, 147, 148].  
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In the study presented in this thesis, HGF was loaded into extracellular matrix 
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CHAPTER 3 
RESEARCH OBJECTIVES  
The preceding literature review has identified the necessity of new strategies 
to treat tendon or ligament injuries. Majority of research on tendon and ligament 
tissue engineering recently were focused on the cell seeded collagen gels. However, 
up to now, no cell-collagen construct has been able to achieve sufficient mechanical 
properties. On the other hand, a better cell source need to be identified for tendon and 
ligament tissue engineering, due to taking tenocytes out would cause donor-site 
morbidity. 
According to the current problems in tendon and ligament tissue engineering, 
our goal in this study is to enhance tissue-engineered grafts maturation and use 
endogenous stem cells for de novo tendon or ligament regeneration and repair. The 
specific objectives of this study are: 
(1) To engineer a functional graft with the similar histological 
structures and mechanical properties as native tendon or ligament 
tissue. Gene therapy would be used as model approach, by which 
cells can over-express genes, such as LOX or decorin, to increase 
collagen cross-linking, which can enhance collagen maturation, and 
optimize collagen fibril formation. 
(2) To attract endogenous stem cells to the lesion site for tendon 
regeneration. ECM-based hydrogel system would be used to 
control the delivery of chemotaxic growth factors, such as 
hepatocyte growth factor (HGF), for recruiting mesenchymal stem 




PART I: CHAPTER 4 
ACCELERATION OF THE MATURATIONOF TISSUE ENGINEERED GRAFTS  
BY GENE THERAPY FOR TENDON OR LIGAMENT REPAIR 
Abstract 
Despite significant progress of tissue engineering technologies has been 
achieved both in academic labs and in industries, a number of difficulties are still 
present which slow down the commercial process of tissue engineered products. For 
tendon and ligament repair by means of tissue engineering, one major difficulty is 
how to gain functional grafts with the similar mechanical properties as the native 
tissues. To overcome the poor performance of engineered tendon tissue grafts on 
histological structures and mechanical properties, we try to accelerate the maturation 
of engineered grafts and optimize the graft structure using gene therapy. The 
maturation of tendon tissue is dominated by the amount and the crosslinkage of the 
extracellular matrices, such as collagen, elastin, glycosaminoglycans, and so on. 
Maturation of collagen and elastin is controlled by the degree of crosslinking in these 
molecules. Crosslinking can occur in various ways, but in vivo most crosslinkings are 
mediated by lysyl oxidase (LOX), which recognizes different binding sites that are 
similar on the type I, II, and III collagens and elastin. On the other hand, decorin is 
considered a key regulator of matrix assembly, and it plays a major role in the 
collagen network organization and in the maintenance of tissue integrity. In this study, 
Infected MEF cells that expressed LOX or decorin were utilized as a model system to  
test our strategies. The results demonstrated that LOX and decorin significantly 
promote tissue maturation indicated by showing the significant increase in the 




Tendons and ligaments are anatomic structures that connect muscles to bones 
or bone to bones and transmit the forces to bones making joint movements possible. 
Healthy tendons, which exhibit high mechanical strength and good flexibility, are 
brilliant white in color and fibro-elastic in texture. Tendon and ligament injuries are 
among the most common injuries to the body, particularly in the young and physically 
active population. The most common tendon disorders are observed in the Achilles 
tendon (100,000 per year) [1], in the rotator cuff in the shoulder (51,000 per year) [2], 
and patellar tendon donor autograft injuries in the knee (42,000 per year) [3]. 
Ligaments are most often torn in traumatic joint injuries that can result in either 
partial or complete ligament discontinuities. For example, over 100,000 anterior 
cruciate ligament (ACL) ruptures estimated to occur each year in the United States[4]. 
All of these tendon and ligament disorders can bring significant morbidity and 
decrease the quality of life. 
Treatment of tendon and ligament disorders has traditionally involved 
reduction of inflammation, restoration of flexibility and surgical repair. When 
inflammation (tendinitis) and degeneration (teninosis) cannot be resolved, primary 
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repairs, autografts [5], allografts [6], and xenografts [7], and resorbable synthetic 
biomaterials [7-9] have been attempted, but with varying success. Recently, tissue 
engineering approaches have been evaluated to treat tendon disorders, based on the 
concept that an improved repair outcome will achieved by combing principles of 
engineering and biology Thus the focus of developing new treatment strategies for 
tissue repair has shifted from transplantation and replacement to biological 
regeneration.  
Recent advances in sophisticated scaffold fabrication, controlled release of 
biomolecules, stem cell biology, and bioreactor development, have raised extensive 
interests in tissue engineering and regenerative medicine-based tissue regeneration 
strategies in academic researchers, clinicians, and biotechnology industries. To date, 
fundamental techniques for tissue engineering both in vitro and in vivo, such as 
scaffold fabrication, controlled release of growth factors and genes, manipulation of 
stem cells and precursors cells, and dynamic bioreactors, have been established for 
clinical translation of tissue engineering strategies. 
Despite significant progress has been achieved both in academic research and 
in industry, a number of difficulties slow down the commercial process. One major 
difficulty is how to gain a functional graft the similar mechanical properties as native 
tissues. To overcome the poor performance of engineered tendon or ligament tissue 
grafts on histological structures and mechanical properties, we try to accelerate the 
maturation of engineered grafts and optimize the graft structure using gene therapy. 
The maturation of tendon tissue is dominated by the maturation degree of 
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extracellular matrix. The maturation of extracellular matrix is proceeded by the 
cross-linking of various components in extracellular matrix, such as collagen, elastin, 
glycosaminoglycans, and so on. Cross-linking of ECM is also an effective approach to 
improve the strength of constructs for tissue-engineering applications. Since collagen, 
which constitutes more than 60% of the dry mass of tendon, is the major component 
of ECM of tendon. The most abundant ligament component is type I collagen as well, 
which constitutes about 80% of the dry mass of the ligament and about 85% of the 
total collagen [10]. The rest collagens in ligament include collagen type III, V, VI, XI, 
and XIV. Type III and V collagen make up 8% of and 12% of the dry weight of the 
ligament, respectively, and they have been shown to be involved in regulating 
collagen fibril diameter [11]. In our study, for tendon or ligament tissue engineering, 
the maturation of collagen type I was focused on. 
The collagen fibers of tendons and ligaments are aligned in a parallel and 
therefore loaded instantly, permitting maximum transfer of the energy of muscle 
contraction to the bone or bone to bone. Collagen has triple-helix structure. Collagen 
synthesis occurs in the endoplasmic reticulum, packaged in the Golgi apparatus and 
excreted to extracellular environment. Maturation/cross-linking of collagen occurs 
outside the cell. The formation of cross-links in mature collagen creates stability and 
gives definition to the structure. The major ways to form cross-links in vitro are 
nonenzymatic cross-linking and enzyme cross-linking. Nonenzymatic cross-linking 
includes glutaraldehyde fixation, sugar-mediated cross-linking and so on. The main 
drawback to glutaradehyde derived crosslinks is that glutaraldehyde-fixed tissues are 
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subject to calcification in vivo. Sugar-mediated cross-link formation, also called 
glycation can form covalent bonds between collagen molecules and increase tissue 
stiffness. Glycation increases a tissue’s platelet aggregation potency and increase the 
potential for thrombosis formation. Collagen cross-links can be mediated by secretory 
enzymes such as lysyl oxidase (LOX). In fact, too few LOX-generated cross-links is 
reported to associate with decreased tissue strength. Protein-lysine 6-oxidase (lysyl 
oxidase, LOX; EC 1.4.3.13), which is expressed and secreted by fibrogenic cells, is a 
copper amine oxidase. LOX initiates the covalent cross-linking of collagen and elastin 
in the extracellular space by oxidizing specific lysine residues in these proteins to 
peptidyl α-aminoadipic-δ-semialdehyde (AAS). These aldehyde residues can 
spontaneously condense with vicinal peptidyl aldehydes or with ε-amino groups of 
peptidyl lysine to generate the covalent crosslinkages, which stabilize and insolubilize 
polymeric collagen or elastin fibres in the extracellular matrix [12]. LOX plays a 
central role in the morphogenesis and repair of connective tissues of the 
cardiovascular, respiratory, skeletal, and other systems of the body. 
Besides collagen, proteoglycans (PGs) play a crucial role in collagen 
fibrillogenesis, and therefore in tendon function. Decorin is the most abundant tendon 
PG. Decorin is considered a key regulator of matrix assembly because it limits 
collagen fibril formation and thus directs tendon remodeling due to tensile forces [13, 
14]. The assumed location of decorin on collagen fibrils in vivo and its ability to 
retard collagen fibrillogenesis in vitro suggest that it has a role in the collagen 
network organization and in the maintenance of tissue integrity[15]. Thus absence of 
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decorin might affect not only fibril formation but also fibril stability within tissues. 
In our study, we used LOX or decorin transfected retrovirus to infect mouse 
embryonic fibroblasts (MEF) to accelerate collagen maturation for tendon repair. 
 
 
Materials and Methods 
Materials 
LOX plasmid was a gift from Dr. Ben Fogelgren. Decorin plasmid was 
purchased from ATCC. DMEM media, FBS, L-glutamine solution, non-essential 
amino acids solution were purchased from Invitrogen. Restriction endonucleases used 
for plasmid construction were purchased from New England Biolabs.  
 
Derivation of mouse embryonic fibroblasts (MEF) 
CF-1 strain mice at 12.5 days gestation were anesthetized. Mouse was placed 
belly up in sterile tissue culture hood. The belly skin was cut using sterilized 
instruments to expose the peritoneum. And then the peritoneal wall was cut and the 
uterine horns were exposed. Uterine horns were removed and put to a new petri dish 
after washing. Then embryonic sacs were open and embryos were released using 
forceps and scissors. Visceral tissue was separated from embryos, and the embryos 
were put in a new plate. Mince tissue with dissecting scissors into grain sized pieces. 
Add 2ml trypsin, and mince for an additional few minutes until pieces are further 
reduced in size. Add an additional 5ml trypsin and place dish into incubator for 20-30 
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minutes. And then vigorously pipet mixture up and down. Add about 20ml MEF 
culture media (DMEM media with 10% FBS, 1% 200mM L-glutamine solution and 
1% non-essential amino acids solution) and transfer contents to a sterile 50ml plastic 
conical tube. Divide the mixture to several T75 flasks. Incubate the flasks containing 
the minced tissue mixture in a 37oC tissue culture incubator overnight. Continue to 
culture the flask until at least 90% of the flask surface is covered with cells. 
 
Plasmid construction  
Plasmid pENTR 1A (Invitrogen) was used to get the entry clones containing 
LOX or Decorin genes. To construct pENTR-LOX plasmid, EcoRI/PmeI double 
digested LOX fragment was ligated with EcoRI/EcoR1V digested pENTR 1A 
fragment. To construct pENTR-Decorin plasmid, BamH1/BglII digested Decorin 
fragment was ligated with BamH1/EcoRV digested pENTR 1A fragment. 
Recombination reactions were then carried out to transfer the LOX or Decorin gene 
into expression vector. Briefly, entry clone was mixed with 
MSCV-IRES-GFP-GATEWAY expression vector and LR clonase II enzyme mix 
(Invitrogen). The mixture was incubated at 25oC for 1 hour, and proteinase K was 
then added to the reaction and incubated for 10 min at 37oC. The recombination 
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Figure 4.1 Plasmid contruction. 
 
 
Retrovirus production  
HEK 293 cells were transfected with effectene transfection system (Qiagen) 
with the expression plasmids MSCV-LOX-IRES-GFP or 
MSCV-DECORIN-IRES-GFP together with packaging plasmid EcoPAC. The amount 
of DNA used for transfection was 4.5μg expression plasmid and 5.5 packaging 
plasmid (molecular ratio 1:1) per 150mm dish. 24 hours after transfection, medium 
was discarded and 10ml fresh medium was added. Medium containing viral particles 
was collected at 48 hours after transfection. Medium was then centrifuged at 3000rpm 
for 15min at 4oC to pellet debris. Supernatant was stored at -80oC until use. 
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Cell infection 
MEF cells were trypsinized and seeded into 6-well plate to grow overnight at 
37oC in a humidified 5% CO2 incubator. 1.5ml viral stock was mixed with 1.5ml fresh 
medium and then added to cells with 30-50% confluence after old medium was 
removed. Polybrene was added to each well to a final concentration of 10 μg/ml. Cells 
were incubated for 24 hours at 37oC in a humidified 5% CO2 incubator. The following 
day, medium was removed and 2ml fresh medium was added to incubate for another 
24 hours. Cells were checked for the efficiency of infection under a fluorescence 
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Figure 4.2 Retrovirus production and MEF cells infection. 
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Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was extracted using Versagene RNA kit (Invitrogen). Reverse 
transcription was accomplished with 5μg of total RNA using the TranscriptTM kit 
(BioRad). PCR was carried out under the following conditions: denaturation at 95oC 
for 1 min, annealing at 55oC for 1 min, extension at 72oC for 1 min (30 cycles), and a 
final extension at 72oC for 10 min. PCR production were analyzed by electrophoresis 
on a 1% agarose gel and visualized with ethidium bromide. The sequences of 

















MEF cells infected with LOX or Decorin expressing retrovirus were lysed 
with lysis buffer, and protein concentration was determined using the BCA kit. 10μg 
of protein lysate and protein marker were run in 10% SDS-PAGE followed by transfer 
to a PVDF membrane. Western analysis was carried out using the following primary 
antibodies: goat polyclonal anti-LOX (E-19) antibody (Santa Cruz), and goat 
polyclonal anti-human decorin antibody (R&D systems). After extensive washing, 
immunocomplexes were detected with horseradish peroxidase-conjugated appropriate 
secondary antibodies followed by enhanced chemiluminescence reaction (ECLTM, 
Amersham). 
 
Preparation of MEF-collagen constructs 
First, collagen type I (rat tail collagen type I, BD Biosciences) gel was 
prepared. Briefly, determine the final volume of collagen solution to be used and the 
desired final collagen concentration (1.6mg/ml). 10X PBS with 1/10 final volume was 
added to the collagen type I. Then 0.023 final volume of 1N NaOH was added into the 
solution. Then appropriate DMEM culture media was added to the mixture to adjust 
the collagen type I to final concentration 1.6mg/ml. Left the mixture on ice until ready 
for use.  
105 cells were mixed with collagen type I gel. Then the cell and collagen gel 
mixture were pipetted into specially designed silicone dishes that permitted 
contraction around posts (Figure 4.3). For each acellular sample, only the collagen 
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(1.6mg/ml) was pipetted into the silicone dish. All constructs remained in an incubator 
(37oC, 5% CO2) for four weeks and were fed high glucose DMEM with ascorbic acid 
and 10% FBS twice weekly. 4 weeks after cell culture, some of the samples were for 










Figure 4.3 Silicon mode. Each silicone dish consists of eight wells into which cells and collagen 




Aligned Polyurethane fibers fabrication (electrospinning) 
Fibers were electrospun from polymer solutions containing a degradable PU 
(synthesized in our lab) based on lysine diisocyanate (LDI, Kyowa Hakko Koygo Co., 
Ltd, Tokyo, Japan).  5-7 wt/v% and degradable PU was dissolved in 
dichloromethane:dimethylformamide (3:1) (DCM:DMF, Sigma) at concentrations of 
13-17 wt/v%. Polymer solution was feed by a syringe pump (Medfusion 2010i; 
Medex Inc.) at adjustable feed rates of 0.010- 0.020 ml/min through 1/16” 
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polyethylene tubing into a 30blunt tipped needle (Smallparts).  A voltage of 10 kV 
was applied to the needle tip with a high voltage power supply (Gamma High Voltage 
ES40P-10W).  The needle tip was held at 10 cm above the level of the collecting device.  
The collecting devices were grounded.  Polymer fibers deposited across the parallel plates 
were collected with a home-made polycarbonate frame.  
 
Cell culture in aligned nano-polyurethane fibers 
The aligned polyurethane fiber frames were sterilized using 1N HCl and 
washed with 1X PBS for several times. 106 normal MEF cells were seeded on the 
nanofibers first. Two days after seeding, the MEF cells were confluent on the fibers, 
and then the frames were turn over for the second time cell seeding. LOX or Decorin 
expressing cells were seeded on the other side of the frames. The cells were cultured 
with high glucose DMEM culture media with ascorbic acid and 10% FBS in 37oC, 
5% CO2 incubator. One week after second time cell seeding, the frames were taken 
out and the nano-fibers with cells were rolled over for animal surgery. One of the 
frames was fixed with 4% Paraformaldehyde, and then stained with Alexa 
546-phalloidin.  
Briefly, the sample was blocked in TBSA-BSAT (10mM Tris-HCl, 150mM 
NaCl, 0.02% sodium azide, 1% Triton X-100) for 1 hour at room temperature, and 
then washed with wash buffer (PBS, with 0.05% sodium azide, 0.05% Triton X-100) 
for 3 times, 10 minutes each. Then the sample was incubated in appropriate diluted 
546-phalloidin solution for 2 hours at room temperature. The sample could be stored 
 66
in the wash buffer at 4oC and for later use. The stained sample was taken pictures 
under Confocal microscope. 
 
In vivo animal surgery 
Nude rats were anesthetized and shaved to facilitate the incision. Incisions 
were made on the back with scissors, and pockets adjacent to the incision site were 
created with the aids of curved forceps. The nano-polyruethane fibers cultured with 
different cells were implanted and the incision was closed. 4 weeks after surgery, the 
samples were taken out from the pockets of rats, and some of them were for the 
mechanical test, and some of them were fixed for histology study. 
 
Histology 
For histology study, the samples were fixed in 10% neutral buffered formalin. 
All samples were then processed through a gradient of alcohols embedded in paraffin 
blocks, sectioned, and stained with hematoxylin and eosin (HE staining).  For Sirius 
red collagen staining, the sections were deparaffinized and rehydrated first. Then the 
sections were dipped in saturated picro-sirius red solution for one hour and washed 
with 0.01 N HCL solution twice for 0.5 minute each. Dehydrate the sample with 100 





 The retrieved samples were tested for mechanical properties using tensile test 
(Bose Inc). The stress strain curves were obtained through a mechanical testing 
software provided by the manufacturer.  
 
Statistics analysis 
Data will be presented as the mean +/- the standard error of mean for each 
group. One-way analysis of variance (ANOVA) will be performed to determine the 
effect of LOX or Decorin on the properties of regenerating tissue. Statistical 
significance is accepted at p< 0.05. 
 
 
Results and Discussion 
LOX and decorin expression in MEF 
Our goal in this study was to implement gene therapy as a tool to optimize the 
performance of mechanically challenged engineered tissue. Mouse embryonic 
fibroblasts were infected with LOX or decorin-expressing retrovirus. RT-PCR 
confirmed the transcription of LOX or decorin genes compared to control group that 
infected with retrovirus with empty vector (Figure 4.4A). LOX or decorin protein 






















































Figure 4.4 LOX and decorin expression in MEF. A) Reverse transcription-polymerase chain reaction 
(RT-PCR) analysis of RNA isolated from control MEF cells and LOX or Decorin expressing retrovirus 
infected MEF cells. B) Western immunoblotting analysis of LOX or Decorin expression in MEF.  
 
 
Mechanical test for in vitro experiment 
After four weeks cell culture, there was significant difference in the strength 
among the groups (Figure 4.5). The maximum load for the control MEF group was 
0.2 ±0.04 N, and the maximum load for the LOX and decorin group was 0.8 ±0.13 N 
and 0.5±0.09N, respectively. The maximum load for the collagen-cell graft 
significantly increased after the cells transfected with LOX or decorin. The collagen- 
cell constructs were 1mm in width and 20mm in length. Young’s modulus of the 
control grafts was 780 ±80KPa, young’s modulus of decorin-expressing group and 

























Figure 4.5 Force-displacement curves of the collagen-cell grafts. (A) Control group. (B) LOX 







































































Figure 4.6 Young’s Modulus of collagen-MEF constructs. 
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Collagen plays a central role in tendon and ligament regeneration, as collagen 
type I is responsible for major composition of the tissue, and its hierarchical 
organization in bundles confers most of the tendon mechanical properties. 
Consequently, tendon engineering studies mainly cell seeded collagen gels. 
Contraction of the gel is related to the cell seeding density, generally followed by 
alignment and reorganization of the matrix [16, 17]. But, up to now, no 
tenocytes-collagen constructs have been able to achieve sufficient mechanical 
properties, and the complex architecture of the tendon is never fully reproduced [18].  
Also, collagen type I does not account for all the tissue properties. The role of 
proteoglycans and small leucine rich protein (SLRP) in the organization and 
mechanical properties of the tissue structure has been recently outlined [19]. In our 
study, in order to enhance mechanical property of cell-collagen grafts, cross-linking 
strategy was used by over-expressing LOX gene in MEF cells. Meanwhile, 
over-expressing decorin gene in MEF cells was also used to enhance the mechanical 
property of the tissue-engineered grafts. Our data showed that the LOX or decorin 
expressing MEF-collagen grafts had much stronger mechanical property than the 
control grafts.  
 
TEM result for in vitro cell culture 
TEM images of collagen fibril diameters are shown in Figure 4.7. Majority 
collagen fibrils in the control cells (blank vector transfected) were 15 ~ 20 nm, in 
LOX-expressing group were 30-35 nm, and in decorin-expressing group were 10~ 15 
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nm. Mean diameters of collagen fibrils in the decroin-expressing group were smaller 































































Figure 4.7 TEM result for in vitro cell culture. A) Control group, B) LOX-expressing group, C) decorin 
-expressing group, and D) The diameter distribution of collagen fibrils. 
 
 
The major proteoglycan in the tendon or ligament is decorin, which anchors to 
d-bands with several collagen fibrils by non-covalent binding [20]. Decorin is 
composed of dermatan sulfate, which is a glycosaminoglycan that affects the 
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morphology and formation of collagen fibrils and core protein by covalent binding 
[21]. It is reported that tendons of animals lacking decorin had collagen fibrils with 
irregular diameters [14]. Down-regulation of decorin has also been shown to be 
correlated with the development of collagen fibrils with large diameters [22]. Our data 
showed that there were significant differences among the diameters of the control 
group, decorin-expressing group, and LOX-expressing group. 
 
Cells aligned after culture in nano-polyurethane fibers 
 Cells in all three groups are aligned well with the direction of oriented nanofibers 
as shown in Figure 4.8. Mouse embryonic fibroblasts attached to scaffolds over a 24-h 
period, after 3 days culture, the cells were aligned well on the oriented nanofibers 
compared to the cells seeded on the normal culture flask (data not shown). One of the 
considerable challenges remaining in the field of tendon and ligament tissue 
engineering is to produce a construct with an anatomically correct architectural 
framework, both in terms of cell morphology and matrix deposition. No cell-collagen 
constructs are able to achieve sufficient mechanical properties, and the complex 
architecture of the tendon is never fully reproduced. It is therefore hypothesized that 
by creating an initial architecture, newly formed ECM will be deposited along the 
prescribed fiber direction in these nanofibrous scaffolds, expediting the formation of a 














Figure 4.8 Cells aligned after culture on biodegradable polyurethane nanofibers. Blue color showed cell nuclei 
stained with draq5 and green color showed transfected cells expressing green fluorescence protein (GFP). 
 
 
Mechanical test for in vivo experiment 
Four weeks after surgery, the grafts were taken out for mechanical test. Our 
data showed that there was significant difference in linear stiffness between the 
groups (Figure 4.9). The maximum load for the control group was 1.8 ± 0.3 N, the 
maximum load for the LOX group and decorin group were 3.5 ± 0.6 N and 3.1 ± 0.5 
N, respectively. The scaffolds were 1mm in diameter and 20mm in length. Young’s 
modulus of the control grafts was 3200 ± 36.1KPa, young’s modulus of 
decorin-expressing group and LOX-expressing group was 4670 ± 52.8KPa and 6130 
± 69KPa, respectively (Figure 4.10). The strength of the graft was significantly 























Figure 4.9 Force-displacement curves of the nanofiber-cell grafts. (A) Control MEF cells. (B) Infected 














































































There are some inconsistent results about the effect of decorin on collagen 
fibrillogenesis and its biomechanical properties. Decorin-deficient mice were reported 
to have fragile skin that is not able to withstand sudden tensile strain. Electron 
microscopic examination of the skin in decorin knockout mice showed coarser, 
irregular and haphazardly arranged collagen fibrils compared with wild type mice[14]. 
Overexperssion of decorin by rat arterial smooth muscle cells enhances contraction of 
type I collagen in vitro[23]. In our study, overexpression of decorin in MEF cells was 
also proved to increase the mechanical property of MEF-collagen graft although the 
mean diameter of collagen fibrils was reduced. While Nakamura et al demonstrated 
that in vivo treatment of injured rabbit ligament by antisense decorin 
oligodeoxynucleotides led to an increased development of larger collagen fibrils in 
early scar and a significant improvement in both scar failure strength and scar creep 
elongation under loading which suggested that down-regulation of decorin helps to 
improve the healing of various soft tissues including tendon and ligament[22]. One 
explanation for that paradox is that decorin uniforms the collagen fibrils leading to 
better-organized collagen structure that has improved mechanical property. It is 
noticeable that the mean diameter of collagen fibrils in decorin-expressing group 
(10-15nm) only showed slight decrease compared with control group (15-20nm). And 
the distribution of diameters of collagen fibrils is more confined in decorin-expressing 
group than in control group. We hypothesize that moderate overexpression of decorin 
can help well organize collagen structure and improve its mechanical property but too 
much decorin may induce the opposite effects by inhibiting collagen fibril formation. 
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In later situation, down-regulation of decorin may be necessary to improve the 
collagen structure. Another explanation is that in our study decorin, which is essential 
for the regulation of newly synthesized collagen, was secreted to regulate the fibril 
formation of soluble collagen molecules while in Nakamura’s work decorin worked 
on existing mature tendon. And the difference of animals used in the experiments 
might also be counted. 
 
Histology 
Sirius red staining was used to examine the maturation of collagen fibrils. When 
examined through crossed polars, the matured collagen fibers are bright yellow or 
light red, and the immature collagen fibers are green. Figure 4.11 shows the Sirius red 
staining of the grafts retrieved from the animals. Immature collagen fibrils were 
dominated in control group (Figure 4.11 A) and decorin-expressing group (Figure 4.11 
C) with overall green staining profile.  Significant more mature collagen fibrils were 












Figure 4.11: Sirius red staining of the grafts retrieved from the animals. (A) Control group. (B) 





Our in vitro and in vivo experiments both showed that the mechanical property of 
tissue-engineered graft could be significantly increased by over-expressing LOX or 
decorin gene in fibroblast cells. The maturity of the collagen fibrils could be improved 
or accelerated by over expressing LOX. The electrospinning technique can help cells 
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PART II: CHAPTER 5 
RECRUITMENT OF ENDOGENOUS STEM CELLS FOR TISSUE REPAIR 
Abstract 
The traditional concept of stem cell therapy envisions the isolation of stem 
cells from patients, propagation and differentiation in vitro, and subsequent 
re-injection of autologous cells to the patient.  There are many problems associated 
with this paradigm, particularly during the in vitro manipulation process and the 
delivery and local retention of re-injected cells. An alternative paradigm that could be 
easier, safer, and more efficient, would involve attracting endogenous stem cells and 
precursor cells to the defect site for de novo tissue regeneration. Hepatocyte growth 
factor (HGF), a pleiotropic cytokine of mesenchymal origin, exerts strong 
chemoattractive effect on mesenchymal stem cells (MSCs) and neural stem cells 
(NSCs), inducing migration of MSCs in vitro. However, HGF undergoes rapid 
proteolysis in vivo, resulting in a very short lifetime of the bioactive cytokine. To 
maintain the therapeutic level of HGF at the defect site necessary for endogenous 
stem cell recruitment, sustained, long-term, and localized delivery of HGF is required. 
Thiol-modified glycosaminoglycans hyaluronan (HA) and heparin (HP), combined 
with modified gelatin (Gtn), were crosslinked with poly (ethylene glycol) diacrylate 
(PEGDA) afford semi-synthetic ECM-like (sECM) hydrogels that can both provide 
controlled growth factor release and permit cell infiltration and proliferation. Herein  
we compare the use of different sECM compositions, for controlled release of HGF 
and concomitant recruitment of human bone marrow MSCs into the scaffold in vitro. 
Also, the stem cells recruitment ability by HGF-loaded scaffolds was demonstrated in 




The traditional concept of cell therapy is based upon several basic steps. The 
first step is cell sourcing and cells may be isolated from autologous, allogenic, or 
xenogenic sources. Second, the isolated cells are expanded in vitro to a cell population 
sufficient for effective treatment. The expanded cells can also be seeded on a scaffold 
and cultured in a bioreactor. Finally, the expanded cells are re-implanted into the 
patient. However, this final process is associated with ethical, economic, regulatory 
and clinical problems.  
Clinically, allogenic and xenogenic sources face the greatest likelihood if 
immune rejection by the patient.  Ethical and regulatory issues must also be resolved 
for this to be a routine clinical treatment. Thus, autologous cells would seem to be the 
best choice, but cell isolation from patients in need of treatment can cause additional 
normal tissue morbidity. In order to obtain sufficient number for transplantation, in 
vitro proliferation is essential, which may cause undesirable phenotype change [1]. 
Pluripotency of stem cells may decrease during in vitro culture [2, 3]. Allogenic and 
xenogenic components used in culture may cause host immune rejection. In addition, 
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the cost for in vitro expansion of stem cells is very high, since a battery of growth 
factors is needed for the propagation procedures. The economic and multi-week 
expansion period present important challenges to these clinical procedures. Finally, 
while mesenchymal stem cells attract much attention due to their pluripotency, the 
pluripotency of mesenchymal stem cells decreases during in vitro culture [2, 3] using 
conventional 2-D culture conditions.  
An alternate cell source could be endogenous stem cells. Indeed, a 
regenerative medicine approach for tissue repair focused on the direct manipulation of 
endogenous adult stem cells is very appealing. There are several advantages to the use 
of endogenous stem cells for tissue repair. First, using endogenous stem cells avoids 
the immunocompatibility issues that accompany the use of allogenic and xenogenic 
cells. Second, it is easier, safer, and more efficient to use endogenous stem cells for 
tissue repair to expand and re-implant autologous cells. Third, only a single surgical 
intervention is required, rather than two surgeries several weeks apart. Finally, the 
process of recruiting endogenous stem cells offers both regulatory and economic 
advantages relative to ex vivo approaches.  
The utilization of endogenous stem cells may be enhanced in two ways. One 
strategy is to mobilize the endogenous stem cells into the circulation. For example, it 
is reported that granulocyte colony-stimulating factor (G-CSF) mobilizes stem and 
progenitor cells from the bone marrow into the peripheral blood, from which they can 
“home” into the lesion site in the brain and have a protective or restorative effect [4]. 
Also, the mobilized endogenous stem cells are showing promising outcome for 
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cardiac repair [5]. A second strategy is to enhance the recruitment of endogenous stem 
cells into the lesion site for tissue regeneration. Several factors, such as hepatocyte 
growth factor (HGF) [6] and stromal cell-derived factor-1 (SDF-1) [7] have shown 
chemotaxic effects on stem cells. In this study, we used HGF as a model factor to 
attract bone marrow mesenchymal stem cells into an ECM-like hydrogel in vitro. 
Hepatocyte growth factor (HGF) has been shown to be a strong chemotactic factor the 
mobilization and migration of mesenchymal stem cells (MSCs) [6]. Exposure of 
MSCs to HGF induced migration of MSCs in vitro. However, like most proteins, HGF 
undergoes rapid proteolysis in vivo, resulting in a very short lifetime of the bioactive 
growth factor. The half-life of HGF that was delivered in a soluble form in vivo is 3-5 
minutes.  In contrast, the time required to recruit a sufficient number of stem cells for 
tissue repair is usually days to weeks. Therefore, direct injection of growth factors to 
the repair site has limited success.  
To maintain the therapeutic level of HGF at the repair site necessary for 
endogenous stem cell recruitment, sustained, long-term, and localized delivery of 
HGF is essential. Several polymer delivery systems are being developed for proteins 
and growth factors delivery. Reservoir devices, solid implants, polymeric micro- and 
nano-particles, and hydrogels are the most commonly used. Polymer systems have 
many advantages; for example, they can stabilize proteins, provide localized delivery, 
and produce diffusion-limited concentration gradients in tissues. ECM-derived 
polymers with a wide array of physiological functions represent ideal substrates for 
HGF delivery and stem cell recruitment, since ECM based materials may provide 
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adhesion sites for migrating stem cells to grow in. Recently, an injectable, in 
situ-crosslinkable semi-synthetc ECM-like hydrogel, or sECM, was created by 
crosslinking thiol-modified hyaluronan (HA) and gelatin (Gtn) using poly(ethylene 
glycol) diacrylate (PEGDA) [8] This material offers a flexible composition and 
compliance, simplicity of use, and was developed for ease of translation from in vitro 
to preclinical in vivo as well as clinical uses [9]. In this study, we compared different 
compositions of the sECM hydrogel for controlled release of HGF to recruit human 
bone marrow mesenchymal stem cells (hMSCs) to the scaffold in vitro. Also, the stem 
cells recruitment ability by HGF-loaded scaffold was evaluated in a subcutaneous 
implantation model in mouse. 
 
 
Materials and Methods 
Materials 
Thiolated chemically-modified HA (CMHA-S), thiol-modified gelatin 
(Gtn-DTPH), thiol-modified heparin (HP-DTPH) and PEGDA were kindly provided 
by Glycosan BioSystems Inc. (Salt Lake City, UT). Bovine serum albumin (BSA), 
4’,6-diamidino-2-phenylindole (DAPI) and heparin were purchased from Sigma 
Chemical Co. (St. Louis, MO). Recombinant human hepatocyte growth factor 
(HuHGF) was purchased from PeproTech (Rock Hill, NJ). Draq 5 was purchased 
from Alexis Corporation. Alexa 546-phalloidin was purchased from Molecular Probes 
Inc. (Eugene, OR).  Recombinant mouse hepatocyte growth factor (mHGF) and 
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Recombinant mouse granulocyte colony stimulating factor (mG-CSF) were purchased 
from R&D Systems, Inc. (Minneapolis, MN). Human HGF ELISA kit was purchased 
from Biosource International, Inc. (Camarillo, CA). 8μm pore size transwells were 
purchased from Corning Costar Inc. (Coring, NY). Rabbit polyclonal CD34 antibody 
and monoclonal Stro-1 antibody were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). Rat anti-mouse Sca-1/Ly6 antibody was purchased from R&D 
Systems, Inc. (Minneapolis, MN). Secondary antibodies, Texas Red F(ab’) Fragment 
Goat Anti-Rat IgG, Cy2 Goat anti-rabbit IgG (H+L) and Cy2 Goat anti-mouse IgG 
(H+L), were purchased from Jackson ImmunoResearch Laboratories, Inc.(West Grove, 
PA). 
 
Hydrogel preparation for in vitro experiments 
Two different sets of hydrogels were prepared. For HA:Gtn gels, CMHA-S 
and Gtn-DTPH in DI water solution (pH 7.4) were mixed in a volume ratio of 1:1, and 
then HA:Gtn solution was cross-linked by mixing it with 2 wt% PEGDA in DI water 
in a volume ration of 4:1. For HA:Gtn:HP gels, HP-DTPH in DI water solution (pH 
7.4) were mixed with the HA:Gtn solution mentioned above: the concentration of HP 
was 0.3%. Hepatocyte growth factor (HGF) was incorporated non-covalently in the 
gels by pre-mixing 500 ng HGF with 200 μL of the modified HA and gelatin solution 




In vitro release kinetics of hHGF 
HGF was allowed to release from these hydrogels at 37 oC into a PBS buffer 
solution supplemented with 1% BSA, 1 mM EDTA, and 10 μg/mL heparin. At days 1, 
2, 3, 5, 9, 14, 20, and 26, 100μl of conditioned medium was sampled, and an equal 
volume of fresh release medium was added back to maintain the total volume. 
Samples were then immediately frozen at -20oC until measurement. Each release 
condition was performed in triplicate. 
 
HGF measurement with enzyme-linked immunosorbent assay (ELISA) 
Released amount of HGF was quantified with sandwich enzymelinked 
immunosorbent assay (ELISA) using an assay from a commercially available kit 
(Biosource). Briefly, 100 μLof the sample was added into the designated ELISA wells 
and incubated at 4 oC overnight. After the incubation, the plate was washed 4 times 
with a wash buffer. Then, 100 μL of biotin antibody was added into each well, and the 
plate was incubated at room temperature for 1h. Then, the plate was washed 4 times, 
and 100 μL Streptavidin solution was added and incubated for 45 min at room 
temperature. Then, the substrate was added to the wells and the absorbance was 
measured at 450 nm. Total accumulated released HGF was calculated by integration 





Human bone marrow derived mesenchymal stem cells culture 
Human bone marrow–derived mesenchymal stem cells (hMSCs) were 
obtained from Lonza (Allendale, NJ). The expression of CD105 and CD 44 
characterized before use for this study. The expression of CD 105 and CD 44 are more 
than 92%. hMSCs were maintained in culture in MSCGM™ - Mesenchymal Stem 
Cell Medium (Lonza, Allendale, NJ).   
 
In vitro experimental procedure for stem cell recruitment 
The migration capacity of hMSCs was analyzed using Costar Transwell 
invasion chambers with polycarbonate membrane filters of 6.5 mm diameter and 8μm 
pore size to form dual compartments in a 24-well tissue culture plate. Samples each 
containing 104 cells in 200 μL of media were added to the upper compartments. The 
lower compartments were covered with 200 μL hydrogels, with or without HGF as a 
source of chemoattractants, and 400 μL culture media were added. The migration 
chambers were incubated for 8 hours at 37 oC and 5% CO2. After incubation, cells on 
the top surface of the filters were wiped off with cotton swabs. Cells that had migrated 
into the lower compartment and attached to the lower surface of the filter were 
counted after being stained with Alexa 546-phalloidin and Draq 5. Briefly, the 
samples were blocked in TBSA-BSAT (10mM Tris-HCl, 150mM NaCl, 0.02% 
sodium azide, 1% Triton X-100) for 1 hour at room temperature, and then washed 
with wash buffer (PBS, with 0.05% sodium azide, 0.05% Triton X-100) for 3 times, 
10 minutes each. Then the samples were incubated in appropriate diluted 
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546-phalloidin solution for 2 hours at room temperature. After 3 times of wash in 
wash buffer, samples were incubated in appropriate diluted Draq 5 for 15 minutes at 
room temperature. Finally, after 2 times of wash in wash buffer, samples were 
incubated in appropriate diluted DAPI solution for 15 minutes at room temperature. 
The samples could be stored in wash buffer at 4oC for later use. The stained samples 
were taken pictures under Confocal microscope. 
 
Polyurethane (PU) scaffolds fabrication 
Three-dimensional, porous, scaffolds were fabricated using a particulate 
leaching technique.  Briefly, 16 wt% of polyurethane (SG80-A, Noveon Inc, 
Cleveland, OH, USA) was dissolved in dimethylacetamide (DMAC, Sigma-Aldrich 
Inc., St. Louis, MO, USA) at 60°C for 12 hours.  Grounded sodium chloride particles 
at 100 ~ 150 μm in diameter were then added into the SG80-A in DMAC solution at 
45 wt% and mixed thoroughly. This was then poured into stainless steel molds, which 
were placed in a dry ice/ethanol bath for 15 minutes. Finally, the molds were dropped 
into distilled water until the scaffolds released from the molds.  The scaffolds were 
then placed into another beaker of distilled for one week to allow the salt to dissolve.  
The scaffolds were frozen at -20 °C for several hours before they were cut into 
rectangular slices (5 mm×3 mm×3 mm). The slices were then washed in distilled 
water for 12 hours before sterilized using ethylene oxide (EtO). The scaffolds were 
immersed into HA-Gtn gel with or without mHGF at 4oC overnight. The next day, the 
scaffolds, which were loaded gel, were picked out and ready for animal surgery. 
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Morphological analysis of the scaffolds was conducted using scanning 
electron microscopy (SEM, JEOL 5410). Scaffolds were allowed to vacuum dry for 
24 hours prior to SEM analysis. The samples were sputter coated with gold at a 
thickness of 50-70 nm using a Cressington 108 AUTO sputter-coater with a current of 
30 mA for 2 minutes. The coated scaffolds were analyzed on a SEM with an 
acceleration voltage of 10 kV. Representative images of the scaffolds were obtained. 
 
Scaffold implantation 
The stem cells recruitment ability was evaluated in a mouse subcutaneous 
implantation model. Male DBA/2 mice aged 6-8 weeks were injected with MG-CSF 
(5μg/100g body weight) for 5 consecutive days through intraperitoneal route. The 
mice were anesthetized and shaved to facilitate the incision. Incisions were made on 
the back with surgical blade, and pockets adjacent to the incision site were created 
with the aids of curved forceps. Six scaffolds (with or without mHGF) were implanted 
per mouse.  
 
Histology 
Seven days after surgery, the mice were anesthetized and perfused. The 
scaffolds were fixed in 10% formalin. The scaffolds were then embedded in paraffin, 
section and stained with stem cell markers (Stro-1), DAPI and Draq 5. Briefly, after 
embedded in paraffin and cut into 10μm sections using microtome. The sections were 
washed with xylene for 5 minutes each, and were incubated in two washes of 100%, 
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95%, 85%, 75%, and 50% ethanol for 10 minutes each. The sections were rinsed 
twice in DI water for 5 minutes each. Incubated the sections in 0.03% H2O2, 80% 
methanol for 30 minutes and rinsed twice in DI water for 5 minutes each. Sections 
were incubated in 10mM sodium citrate buffer pH6.0 at room temperature for 1 hour 
and then boiled using water bath or microwave and maintain at 95-99oC for 10 
minutes. Sections were cooled to room temperature, rinsed in DI water three times for 
5 minutes each, and rinsed in PBS for 5 minutes. Sections were blocked in 4% goat 
serum in PBS for 1 hour. Primary antibodies (Stro-1) were prepared as indicated on 
manufacturer datasheet in 1XPBS with 4% goat serum. After blocking, primary 
antibody was applied. Sections were incubated at 4oC overnight. The specimens were 
rinsed three times in 1XPBS with 0.3% Triton X-100 for 5 minutes each. Then the 
specimens were incubated in appropriate secondary antibodies for 2 hours. After 3 
times washing in wash buffer, samples were incubated in 1:10,000 diluted Draq 5 for 
15 minutes at room temperature. Finally, after 2 times washing in 1XPBS, sections 
were incubated in appropriate diluted DAPI solution for 15 minutes at room 




Data will be presented as the mean +/- the standard error of mean for each 
group. One-way analysis of variance (ANOVA) will be performed to determine the 
effect of HGF loading on the recruitment of stem cells. Statistical significance is 
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Cumulative in vitro HGF release from ECM-based hydrogel 
HGF release profiles from the hydrogel with or without heparin were in vitro. 
Immobilization of heparin in HA-Gtn based hydrogel may protect growth factors from 
enzymatic degradation and thermal denaturation [10]. These crosslinked 
heparin-containing hydrogel behave in an analogous fashion to a heparan sulfate 
proteoglycan, extending the release times of growth factors in vitro and in vivo while 
retaining their bioactivity [11, 12]. Figure 5.1 presents the time course of total 
cumulative release for HGF. Covalently cross-linked heparin slows down the HGF 
release significantly in HA: Gtn based gels, but also reduces the net quantity released 
at a given time point. Without heparin, HA: Gtn gels released a total of 35% of the 
initially loaded HGF in 26 days. In contrast, HA: Gtn: HP gels released a total of 18% 
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Figure 5.1 Cumulative in vitro HGF release from HA: Gtn and HA: Gtn: HP hydrogels. (A) Release 







Bone marrow mesenchymal stem cells migration in vitro 
In this experiment, four groups were assigned. In the negative control group, no 
HGF was present in either the lower or upper compartment of Transwells. In the 
positive control group, 20 ng/mL HGF was present in the culture media of the lower 
compartment of Transwell. In the third group, 500 ng of HGF encapsulated in an HA: 
Gtn gel was placed in each lower compartment. In the fourth group, 500 ng of HGF 
encapsulated in HA: Gtn: HP gel was placed in each lower compartment. 
In order to analyze the migration ability of hMSCs in response to released 
HGF, two locations were observed under a confocal microscope: the lower surface of 
the filter and the hydrogel in each lower compartment (Figure 5.2). Figure 5.3 shows 
the number of hMSCs that migrated to the lower surface of the filter. All four groups 
(Figure 5.3B, 5.3C, 5.3D) showed significantly greater number of MSCs on the lower 
surface of the filter than the negative control group (Figure 5.3A). Figure 5.4 presents 
the cell density in cells per mm2 on the lower surface of the filter. Significantly more 
MSCs migrated across the filter than for each group relative to the negative control.  
The numbers of cells recruited into the hydrogels in the lower compartments 
were also determined. Large numbers of cells were found inside the HA: Gtn gel 
loaded with 500 ng of HGF (Figure 5.5C). Indeed, significantly more cells were found 
in the HA: Gtn gel loaded with 500 ng of HGF (Figure 5.5C) than in any of the other 
three groups: negative control group without HGF loading (Figure 5.5A), positive 
control group with 20 ng/mL of soluble HGF in medium (Figure 5.5B), and the HA: 
Gtn: HP hydrogel loaded with 500 ng of HGF (Figure 5.5D). Paradoxically, no cells 
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were found in HA: Gtn: HP gel loaded with 500 ng HGF Figure (5.5D), similar to the 




































Figure 5.2: 8μm pore size transwell. The device includes two compartments: the lower 
compartment and the upper compartment. The insert has a polycarbonate membrane with 8.0µm Pores. 











Figure 5.3: MSCs across the 8 μm pores to the lower surface of the filter. (A) Negative control (no 
 
HGF), (B) positive control (20 ng/mL HGF in culture media), (C) 500 ng HGF encapsulated in HA: 
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Figure 5.5: MSCs migrated into the hydrogels on the lower compartment . (A) Negative control (no 
HGF), (B) positive control (20 ng/ml HGF in culture media), (C) 500 ng HGF encapsulated in HA: Gtn 
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Figure 5.6: The number of MSCs migrated into the hydrogels on the lower compartment. 
 
 
SEM for porous polyurethane (PU) scaffolds and hydrogel scaffolds 
Figure 5.7 shows the scanning electron microscopy (SEM) images of 
Polyurethane (PU) scaffold. Leaching is one popular approach used in tissue 
engineering to fabricate porous scaffolds. Pores or channels are created using 
porogens, such as salt (NaCl), wax, or sugar. In this study, NaCl was used for pores 
making. For particle leaching, pores are regulated by the salt particles and 100μm-150 
μm salts were used, so that the pores would be around 100 μm-200μm and larger than 
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the cells size (about 15μm). After the solvent (DMAC) was removed and the salt was 
washed, pores can be seen in the interior and on the surface of the scaffold under SEM 
(figure 5.7), and the pores are well interconnected throughout the scaffold. There is 














Mesenchymal stem cells recruitment in a mouse subcutaneous implantation model 
In order to evaluate the stem cell recruitment potential of HGF loaded 
scaffolds in vivo, a subcutaneous implantation mouse model was used. According to 
the profile of the cumulative in vitro HGF release, HA:Gtn hydrogel was chosen for 
the in vivo study. In order to identify the implant at the time of scaffold harvesting, 
 100
HA:Gtn hydrogels were infiltrated into nondegradable polyurethane porous scaffolds 
The scaffolds with or without mHGF loading were implanted to the back of the mice, 
and 1 week after surgery, the scaffolds were processed for immuno-staining and 
visualized under confocal laser microscope.  
First, the number of cells infiltrated into the porous scaffold was quantified 
and compared among groups (Figure 5.8 A, D, and G). Significantly more cells were 
detected in the mHGF releasing scaffolds (Figure 5.8 D) than the control scaffolds 
(Figure 5.8 A) without mHGF loading. This data demonstrated that more cells could 
be recruited to the mHGF releasing scaffolds. In order to identify whether there are 
stem cells among the recruited cells, mesenchymal stem cell marker, Stro-1, was used 
to identify non-hematopoietic stromal stem cells [31]. Our data show that about 
14.2±3.6 % of recruited cells expressed mesenchymal stem cell marker (Stro-1) in the 
scaffolds loaded with mHGF. While in the non-mHGF releasing scaffolds, the 
percentage of the cells expressed Stro-1 is significantly lower at 7.9±1.3 %. This 
demonstrated that scaffolds loaded with HGF may recruit more stem cells to the local 




















































Figure 5.8 Cells migrated into the scaffoldss after 1-week implantation. A-C) Scaffold without mHGF 
release, D-F) scaffold with mHGF release, A,D) Nuclei staining in blue, B and E) Stro-1 Staining in 
green. C and F) The overlay images of nuclei staining and Stro-1 staining. G) The number of cells in 






Thiolated hyaluronan are biocompatible and can be adapted to produce a variety 
of desirable biologic effects [13]. Gelatin is a partially hydrolyzed collagen product, 
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which is an excellent substrate for cell attachment, proliferation, and differentiation. 
Both thiolated HA [14, 15] and thiolated gelatin [16, 17] have been used in a number 
of tissue engineering applications, including the delivery of basic fibroblast growth 
factor (bFGF) for cutaneous wound repair [18] and human demineralized bone matrix 
for bone repair [19]. The hydrogels created by co-crosslinking thiol-modified HA with 
thiol-modified gelatin produces mechanically robust, bioresorbable scaffolds that can 
be implanted to achieve tissue growth in vivo[13, 20-22]. The HA-Gtn hydrogel is 
also an effective vehicle for cell delivery and retention in vivo, including the repair of 
osteochondral defects using encapsulated autologous MSCs [23]. Growth factors 
delivered locally using the HA-Gtn hydrogels elicit a strong angiogenic response, 
even when the growth factors are delivered in low, nanogram doses [11-13, 24]. In 
addition, it is reported that incorporation of small amounts of heparin in the gels can 
prolong and spatiotemporally regulate the rate of growth factor release in vitro [11, 
12]. In this study, we demonstrated that through delivery of HGF from 
heparin-containing HA: Gtn hydrogels or HA: Gtn hydrogel only, the biologic activity 
of HGF can be maintained, and the human mesenchymal stem cells are most 
effectively recruited into the HGF releasing hydrogels when the release rate is 
maintained to certain threshold.  
As commonly occurs with highly bioactive polypeptides in vivo, HGF undergoes 
rapid proteolysis and has a half-life in vivo of 3-5 minutes. Figure 5.1 illustrated that 
release of HGF from crosslinked thiol-modified HA and gelatin hydrogel in vitro 
could be sustained for up to 3 to 6 months based on the extrapolated value from a 
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26-day study. This is a dramatic increase in time of availability compared to the short 
half-life of free HGF in vivo. Furthermore, the rate of HGF release could be controlled 
with heparin. In the absence of heparin, HGF released twice as fast from HA:Gtn 
hydrogel than the HA:Gtn:HP hydrogel. This result is consistent with extended release 
of bioactive keratinocyte growth factor (KGF), vascular endothelial growth factor 
(VEGF), angiopoetin-1 (Ang-1), and bFGF from similar heparan-sulfate mimetic 
hydrogels [10-12] 
The biological activity of the HGF released from the hydrogels was confirmed 
by in vitro hMSCs migration experiments. On the lower surface of each filter, all 
groups except the negative controls showed an obvious accumulation of cells (Figures 
5.3 and 5.4). In the hydrogels in the lower compartments, many cells migrated into the 
HA: Gtn gel loaded with 500ng HGF, while there were few cells attached on the 
negative control group or the HA:Gtn :HP gel loaded with 500ng HGF (Figures 5.5 
and 5.6). This seemingly paradoxical result seems to indicate that the amount of 
loading and the release rate of HGF from the gel are both crucial parameters affecting 
the migration of hMSCs. If the release rate or amount of HGF is lower than the 
threshold for hMSC to response, there will be no control of hMSCs to migrate, since 
when we double the amount of HGF loading into the HA-Gtn-HP gel to 1000ng, 
significant amount of hMSCs migrated into the HA-Gtn-HP hydrogels. According to 
cumulative release of hHGF from two types of hydrgels (Figure 5.1), HA:Gtn 
hydrogel released about 10% of total stored hHGF (about 50ng)at the first two days, 
while HA:Gtn:HP hydrogel released less than 5% of total loaded hHGF (less than 
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25ng) at the first two days. In the literature, the minimum effect dosage for HGF 
activating mesenchymal stem cell migration was 20ng/ml [13, 27]. In our experiment, 
the incubation time for the mesenchymal stem cells migration was short (8 hours), 
hHGF did not have enough time to release to the amount that can attract stem cell 
migration efficiently, especially the HA-Gtn_HP hydrogel. 
The other interesting indication is the importance of HGF gradient in the control 
of MSC migration. If we compare the 20 ng/mL HGF group (Figure 5B) with the 
500ng/mL group (Figure 5C), fewer MSCs are migrated to the hydrogel in 20ng/ml 
group (Group II) than that in slow releasing group (Group III). There are sufficient 
amount of HGF in group II for MSC to migrate, however, the difference between 
group II and III is the establishment of HGF gradient. HGF gradient is well 
established in group III due to the constant release of HGF from the HA-Gtn 
hydrogel. 
In vivo study further verified the observation in vitro. There were significant 
more cells observed in the mHGF-loaded scaffolds than that in control scaffolds 
(Figure 5.8 G). The total numbers of recruited stro-1 positive mesenchymal stem cells 




The release characteristics of HGF and stem cell recruitment capacity of a 
series of HA-Gtn hydrogels loaded with HGF have been investigated in vitro and in 
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vivo. These hydrogels provide sustained release of biologically active HGF in vitro 
and in vivo, with HGF release sustained for over three weeks. This is a dramatic 
increase in time of availability compared to the short half-life of free HGF in vivo. 
HGF released from HA: Gtn hydrogel attracted human bone marrow MSCs to migrate 
into the hydrogel following the HGF gradient established by HGF loaded HA-Gtn 
hydrogels. To evaluate the stem cell recruitment ability in vivo, subcutaneous 
implantation mouse model was used. Significantly more cells were detected in the 
mHGF releasing scaffolds than the control scaffolds without mHGF loading. 
Mesenchymal stem cell marker, Stro-1, can be detected in the recruited cells. Our in 
vitro and in vivo studies demonstrated that stem cells could be recruited to the local 
site where HGF was released by chemically modified HA and modified gelatin based 
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In the tissue maturation part of this thesis, we figured out that 
over-expression of LOX or decorin genes in cells could increase the stiffness of 
tissue-engineered grafts respectively by different mechanism. LOX cross-links 
collagen molecules to enhance collagen maturation, while decorin increases the 
stiffness of the grafts by uniforming the diameter of collagen fibers and regulating 
collagen fibrogenesis. In our future study, we are going to over-express both LOX and 
decorin to figure out whether they can further increase the stiffness of the graft, and to 
design a graft that has similar mechanical and functional characteristics of the native 
tissue in a short period of time. 
The second part of this thesis is to use endogenous stem cells for tendon and 
ligament regeneration. Our in vitro and in vivo studies demonstrated that stem cells 
could be recruited to the local site where HGF were released by chemically modified 
HA and gelatin based hydrogels. In the future work, we plan to optimize heparin 
concentration in the hydrogel for growth factor releasing profile that best promotes 
stem cell recruitment. Furthermore, we are going to control the differentiation of the 
recruited stem cells into desirable cell types by controlling release of differentiation 
factors. 
 
